CURRICULUM VITAE LYNN G. DRESSLER

CONTACT INFORMATION: Business Address: Lynn G. Dressler, Dr.P.H. Director, Personalized Medicine and Pharmacogenomics Mission Health Fullerton Genetics Center 11 Vanderbilt Park Drive, Suite 1500 Asheville, NC 28803 Office phone: 828-213-0025 Email: lynn.dressler@msj.org Assistant: Paige Krug (paige.krug@msj.org) EDUCATION 2005-07 Fellowship, Bioethics Case Western Reserve University,

Department of Bioethics, Center for Genetic Research, Ethics and Law (Mentor: Eric Juengst).

2003 Dr. P.H., Health Policy University of North Carolina School of Public Health

Public Health Leadership Program (Mentor: Arnie Kaluzny)

1981 M.A., Experimental Pathology State University of New York

Buffalo, NY

1978 BA, Biological Science William Paterson College, New Jersey

PROFESSIONAL EXPERIENCE 2/11/13-Present: Director, Personalized Medicine and Pharmacogenomics Mission Health, Fullerton Genetics Center, Asheville NC

Adjunct Professor, University of North Carolina at Chapel Hill (Schools of Medicine and Eshelman School of Pharmacy)

10/2007-2/8/13: Associate Director for Policy and Ethics Institute for Pharmacogenomics and Individualized Therapy (IPIT)

Director, Research Ethics Consultation Service, UNC Center for Genomics and Society

Assistant Professor University of North Carolina at Chapel Hill

Division of Pharmaceutical Outcome and Policy (DPOP)

(Joint Appointment: School of Medicine/Division Medical Oncology)

LYNN G. DRESSLER CURRICULUM VITAE

2

Case Western Reserve University 9/2005-9/2007 Post Doctoral Fellow Case Western Reserve University Department of Bioethics Center for Genetic Research Ethics and Law (CGREAL) NIH/NHGRI Center of Excellence in Ethical, Legal, Social Implications of Genetic Research (CEER) Mentor: Dr. Eric Juengst UNC-School of Medicine: 3/2004- 9/2007 Research Associate Professor 10/1996-2/2004 Research Assistant Professor 10/1996-9/2005 Director, LCCC Immunohistochemistry (IHC) and Tissue Procurement Cores 10/1996-9/2007 Director, IHC Breast SPORE Laboratory 8/1993-10/1996 Clinical Research Coordinator, Flow Cytometry Core Facility

University of North Carolina, School of Medicine Division of Medical Oncology, Lineberger Comprehensive Cancer Center:

University of Arizona Health Sciences Center: 8/1992-7/1993 Clinical Consultant, Department of Pathology University of Arizona Health Sciences Center, Tucson, Arizona 8/1992-7/1993 NCI Pre-Doctoral Research Fellow Division of Tumor Biology University of Arizona Health Sciences Center Tucson, AZ. University of New Mexico: 1991-7/1992 Research Scientist 1987-1990 Staff Scientist 1987-1992 Technical Director, Solid Tumor Facility

University of New Mexico Cancer Center Center for Molecular and Cellular Diagnostics Albuquerque, New Mexico

University of Texas Health Science Center, San Antonio: 1987-1987 Instructor of Medicine 1985-1986 Senior Research Associate 1983-1985 Research Associate University of Texas, Health Sciences Center at San Antonio, Department of Medicine/Oncology Roswell Park Memorial Cancer Institute: 1981-1983 Research Associate Roswell Park Memorial Institute of Cancer Research Experimental Therapeutics

LYNN G. DRESSLER CURRICULUM VITAE

3

Buffalo, NY State University of New York, Buffalo: 1979-1980 Graduate Teaching Assistant

General Pathology Laboratory State University of New York at Buffalo

Honors, Boards, Awards 2014 Advisory Committee Executive Board Member, North Carolina Biotechnology Center, Western Division 2013-Present: Institute of Medicine (IOM) Roundtable Participant: Translating Genomic Medicine into Health 2012-2014: Advisory Board Member. North Carolina Personalized Medicine Center for Innovation. 2012 GENOME CANADA Study Section. Grant reviewer. Toronto, CANADA 2011 NHGRI Study Section. Grant reviewer: Special Emphasis Panel for eMERGE UO1’s. 2010 NHGRI Strategic Planning Session. Airlie, VA. July. 2009 NIH/NHGRI Study Section (P50/P20). Grant reviewer. Special Emphasis Panel for the review of

Centers of Excellence in Ethical, Legal, Social Implications of Genetic Research (CEER). 2008 UNC Nominee for the Greenwall Foundation Faculty Scholar Award in Bioethics. 2006 NIH/NHGRI Post-doctoral Fellowship Award in Ethical, Legal, Social Implications of Genetic

Research. 2005 Institutes of Medicine (IOM) Cancer Advisory Board invitation for background paper on human

specimen biobanking and cancer drug development. 1992 Distinguished invitation to present and participate in the International Breast Cancer Consensus

Conference on the Treatment of Breast Cancer. St. Gallen, Switzerland, February 26-29. 1992 NIH/NCI Pre-doctoral Fellowship Award in Tumor Biology. University of Arizona Health Sciences

Center. 1990 Distinguished invitation to present and participate in the NIH/NCI Consensus Development

Conference on the Treatment of Early Stage Breast Cancer. Prognostic Impact of DNA Flow Cytometry Measurements in the Node Negative Breast Cancer Patient. Bethesda, MD.

1990 Recipient of V.I.P. Award for Loyal and Dedicated Service to the University of New Mexico Cancer Center.

1987 Susan G. Komen Foundation Award: Recipient of Susan G. Komen Breast Cancer Research Award, Sponsored by the Dallas Commercial Real Estate Women

1978 Recipient of C. Kent Warner Award for Outstanding Senior in Biology at the William Paterson College of New Jersey

1978 Magna Cum Laude Grade, William Paterson College of New Jersey PUBLICATIONS (19 books/book chapters; BOOK:

Robinson, J. P. (Ed.), Darzynkiewicz, Z., Dean, P., Dressler, L. G., Tanke, H. and Wheeless, L. (Assoc. Eds.). (1993). Handbook of Flow Cytometry Methods (2nd ed.). New York, NY: Wiley-Liss.

BOOK CHAPTERS:

Dressler, L. G. (2009). Biobanking and disclosure of research results: Addressing the tension between

professional boundaries and moral intuition. In Solbakk, J. H., Holm, S. and Hoffmann, B. (Eds.), The ethics of research biobanking (pp.85-99). New York, NY: Springer.

LYNN G. DRESSLER CURRICULUM VITAE

4

Dressler, L. G. (1997). Flow cytometric analysis of DNA content in solid tumors. In Methods in clinical laboratory immunology (Vol. 5). Dressler, L. G. (1997). Flow cytometric analysis of DNA content in solid tumors. In N. Rose, E.C. de Macario, J. Foldo, H.C. Lane, Nakamura (Eds.), Manual of clinical laboratory immunology (5th ed.). (Chapter 37 ). Washington, DC: ASM Press. Dressler, L. G. and Seamer, L. A. (1994). Standards, controls and histogram interpretation in clinical DNA flow cytometry. In Z. Darzynkiewicz, P. Robinson, P. & H. Crissman (Eds.), Methods in cell biology, (2nd ed.). New York, NY: Academic Press. Dressler, L. G. (1993). DNA flow cytometry and clinical trials in breast cancer. In T. Ensley & F. Valeriote (Eds.), Cytometry 2000. New York, NY: Springer-Verlag. Dressler, L. G. (1993). Paraffin embedded tissue preparation (Method 2). In J. Robinson (Ed.), Z. Darzynkiewicz, P. Dean, L. Dressler, H. Tanke, & L. Wheeless (Assoc. Eds.), Handbook of flow cytometry methods (2nd ed.) (pp. l03-105). New York, NY: Wiley-Liss. Dressler, L. G. (1993). Controls, standards and histogram interpretation in DNA flow cytometry. In J. Robinson (Ed.), Z. Darzynkiewicz, P. Dean, L. Dressler, H. Tanke, & L. Wheeless (Assoc. Eds.), Handbook of flow cytometry methods (2nd ed.). (pp. 90-92). New York, NY: Wiley-Liss. Dressler, L. G. (1993). DNA flow cytometry measurements and their clinical relevance in node negative breast cancer patients. In H. Senn, A. Goldhirsch & R. Gelber (Eds.), Adjuvant therapy of primary breast cancer IV, recent results in cancer research (Vol. 127). (pp. 61-69). New York, NY: Springer-Verlag. Dressler, L. G. (1990). The clinical significance of S phase and ploidy in human solid tumors: Focus on breast cancer. In J. Frei (Ed.), DNA flow cytometry: Status and controversies (pp. 55-67). Toronto, Canada: Plenum Publishing. Dressler, L. G. (1990). Controls, standards and histogram interpretation in DNA flow cytometry. In Z. Darzynkiewicz & H. Crissman (Eds.), Methods in Cell Biology (Vol. 33). (pp. 157-172). New York.

Dressler, L. G, Clark, G. M., Owens, M. A., & McGuire, W. L. (1987). DNA flow cytometry and its relationship to clinical variables in breast cancer. In E. Voigt (Ed.), Progress in cancer research and therapy: Hormones and cancer 3 (Vol. 35). (pp. 394-400). London, England: Raven Press. McGuire, W. L., Fuqua, S. A. W., & Dressler, L. G. (1987). Monoclonal antibody studies of drug resistance. In R. Ceriani (Ed.), 2nd International Workshop on Monoclonal Antibodies and Breast Cancer. New York, NY: Plenum Publishing Corp. Dressler, L. G., Clark, G. M., Owens, M. A., & McGuire, W. L. (1986). DNA flow cytometry and steroid receptors. In S. Iacobelli (Ed.), First international congress on cancer and hormones. Lancashire, England: Parthenon Publishing.

LYNN G. DRESSLER CURRICULUM VITAE

5

McGuire W.L., Clark G.M., Dressler L.G., and Owens M.A. (1986). Predicting recurrence and survival in primary breast cancer. In S. Iacobelli (Ed.), First international congress on cancer and hormones. Lancashire, England: Parthenon Publishing. McGuire W.L., Clark G.M., Dressler L.G., & Owens, M.A. (1986). Assessing prognosis in primary breast cancer. In A. Carpi & A. Nicolini (Eds.), National meeting on breast tumors. Rome, Italy. Edwards D.P., Dressler L.G., Zava D.T., and McGuire W.L. (1986). Monoclonal antibody characterization of a tumor-associated breast cancer antigen. In I. Clement (Ed.), Tumor markers and their significance in the management of breast cancer (pp. 71-88). New York: Alan R. Liss Inc. LeMaistre C.F., Edwards D.P., Dressler L.G., Lathan B., Mansel R.E., & McGuire W.L. (1985). Studies with monoclonal antibodies to breast tumors. In R. Cerianai (Ed.), Monoclonal antibodies and breast cancer (pp. 80-85). Boston, MA: Martinus Nijhoff.

Refereed Papers

Published/in-press: Dressler LG, Deal AM, Patel J, Markey J, VanRiper M, McLeod HL. Cancer pharmacogenomics, adoption by oncologists and patient benefit. (2014). Future Medicine. Personalized Medicine 11(2): 143-153. Dressler LG, Jones SS, Markey JM, Byerly KW and Roberts MC. Genomics education for the public: Perspectives of genomic researchers and ELSI advisors (2014). Genetic Testing and Molecular Biomarkers . 18(3):131-140. Dressler, LG. Integrating Personalized Genomic Medicine Into Routine Clinical Care: Addressing the Social and Policy Issues of Pharmacogenomic Testing. North Carolina Medical Journal. (2013) 74(6): 509-513. Dressler, Lynn G. RETURN OF RESEARCH RESULTS FROM PHARMACOGENOMIC VERSUS DISEASE SUSCEPTIBILITY STUDIES: WHAT’S DRUGS GOT TO DO WITH IT? Pharmacogenomics. (2012). 13(8), 935-949. Esserman LJ, Berry DA, Demichele A, Carey L, Davis SE, Buxton M, Hudis C, Gray JW, Perou C, Yau C, Livasy C, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, van 't Veer L, Hylton N. Pathologic Complete Response Predicts Recurrence-Free Survival More Effectively by Cancer Subset: Results From the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. J Clin Oncol. 2012 May 29. [Epub ahead of print]

ESSERMAN LJ, BERRY DA, CHEANG MC, YAU C, PEROU CM, CAREY L, DEMICHELE A, GRAY JW, CONWAY-DORSEY K, LENBURG ME, BUXTON MB, DAVIS SE, VAN'T VEER LJ, HUDIS C, CHIN K, WOLF D, KRONTIRAS H, MONTGOMERY L, TRIPATHY D, LEHMAN C, LIU MC, OLOPADE OI, RUGO HS, CARPENTER JT, LIVASY C, DRESSLER L, CHHIENG D, SINGH B, MIES C, RABBAN J, CHEN YY, GIRI D, AU A, HYLTON N; I-SPY 1 TRIAL INVESTIGATORS. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I- SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).BREAST CANCER RES TREAT. 2012 APR;132(3):1049-62. DOI: 10.1007/S10549-011-1895-2. EPUB 2011 DEC 25.PMID: 22198468

LYNN G. DRESSLER CURRICULUM VITAE

6

Jeffrey Peppercorn, Iuliana Shapira, Teressa Deshields, Deanna Kroetz,Paula Friedman, Patty Spears, Deborah Collyar, Lawrence N. Shulman, Lynn Dressler, Monica M. Bertagnolli. (2012). "Ethical Aspects of Participation in the Database of Genotypes and Phenotypes (dbGaP) of the National Center for Biotechnology Information (NCBI): The Cancer and Leukemia Group B." Cancer 2012 Mar 13. doi: 10.1002/cncr.27515. [Epub ahead of print]. Lynn G. Dressler, DrPH, Sondra Smolek, PhD, Roselle Ponsaran, MA, Janell M. Markey, MS, Helene Starks, PhD, MPH, Nancy Gerson, BS, Susan Lewis, MSSA, Nancy Press, PhD, Eric Juengst, PhD, Georgia L. Wiesner, MD, for the GRRIP Consortium. (2012) IRB Perspectives on the Return of Individual Results from Genomic Research. Genetics in Medicine. 14(2):215-222. Edwards KL, Lemke A, Trinidad S, Lewis S, Starks H, Snapinn K, Quinn Griffin M, Wiesner, Burke W, the GRRIP Consortium (including Lynn Dressler). Genetics researchers’ and IRB professionals attitudes toward genetic research review: a comparative analysis. Genetics in Medicine 14 (2): 236-242.

Esserman LJ, Berry DA, Cheang MC, Yau C, Perou CM, Carey L, DeMichele A, Gray JW, Conway-Dorsey K, Lenburg ME, Buxton MB, Davis SE, van't Veer LJ, Hudis C, Chin K, Wolf D, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Livasy C, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, Au A, Hylton N; I-SPY 1 TRIAL Investigators. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat. 2012 Apr;132(3):1049-62. Epub 2011 Dec 25.

Jonathan F. Lara, MD, Ann D. Thor MD, Lynn G. Dressler DrPH, Gloria Broadwater MS, Ira J. Bleiweiss, M.D., David Cowan MT , Susan Edgerton MA, Lori J. Goldstein MD, Silvana Martino DO, James N. Ingle MD, I. Craig Henderson MD, Larry Norton MD, Eric P. Winer MD, Clifford A. Hudis MD, Matthew J. Ellis MBBS, PhD, Donald A. Berry PhD, and Daniel F. Hayes, MD (2011). p53 Expression in Node Positive Breast Cancer Patients: Results from the Cancer and Leukemia Group B (CALGB) 9344 Trial (159905). Clinical Cancer Research 17 (15):5170-8. Epub 2011 June 21. PMID :21693655.

Amy L. McGuire, Melissa Basford, Lynn G. Dressler, Stephanie M. Fullerton,Barbara A. Koenig, Rongling Li, Cathy A. McCarty, Erin Ramos, Maureen E. Smith, Carol P. Somkin, Carol Waudby, Wendy A. Wolf, Ellen Wright Clayton. (2011). Ethical and Practical Challenges of Sharing Data from Genome-Wide Association Studies: The eMERGE Consortium Experience. Genomic Research 21(7): 1001-7. Epub 2011 June 01. PMID:21632745.

K.L. EDWARDSA, A.A. LEMKEC, S.B. TRINIDADB, S.M. LEWISD, H. STARKSB, M.T. QUINN GRIFFINE, G.L. WIESNERF, THE

GRRIP CONSORTIUM (INCLUDING LYNN G. DRESSLER). ATTITUDES TOWARD GENETIC RESEARCH REVIEW: RESULTS FROM A

SURVEY OF HUMAN GENETICS RESEARCHERS. PUBLIC HEALTH GENOMICS 14(6):337-45. EPUB 2011. APRIL 11. PMID: 21487211 O”BRIEN KATIE, COLE STEPHEN R, TSE CHIU-KIT, PEROU CHARLES, CAREY LISA, FOULKES WILLIAM D, DRESSLER LYNN

G,GERADTS JOSEPH, MILLIKAN ROBERT C (2010). INTRINSIC BREAST CANCER SUBTYPES, RACE AND LONG-TERM SURVIVAL IN

THE CAROLINA BREAST CANCER STUDY. CLINICAL CANCER RESEARCH.16(24): 6100-10.

RAKHRA-BURRIS TK, AUMAN JT, DEVERKA P, DRESSLER LG, EVANS JP, GOLDBERG RM, HAVENER TM, HOSKINS JM, JONAS

DE, LONG KM, MOTSINGER-REIF AA, IRVIN WJ, RICHARDS KL, ROEDERER MW, VALGUS JM, RIPER M, VERNON JA, ZAMBONI WC, WAGNER MJ, WALKO CM, WECK KE, WILTSHIRE T, MCLEOD HL (2010). INSTITUTIONAL PROFILE. UNC

LYNN G. DRESSLER CURRICULUM VITAE

7

INSTITUTE FOR PHARMACOGENOMICS AND INDIVIDUALIZED THERAPY: INTERDISCIPLINARY RESEARCH FOR INDIVIDUAL CARE. PHARMACOGENOMICS. JAN;11(1):13-21. PMID: 20017668 Khleif Samir H, Doroshow James and Hait William N for the AACR-FDA-NCI Cancer Biomarkers Collaborative (including Lynn Dressler). (2010). AACR-FDA-NCI Cancer Biomarkers Collaborative Consensus Report: Advancing the use of biomarkers in cancer drug development. Clinical Cancer Research 16(13), 3299-318. PMID: 20501613. Lemke Amy, Trinidad Susan B, Edwards Karen L., Starks Helene, Wiesner Georgia and the GRRIP Consortium (including Lynn Dressler). (2010). Attitudes toward Genetic Research Review: Results from a National Survey of Professionals involved in Human Subjects Protection. Journal of Empirical Research on Human Research Ethics. 5(1), 83-91. PMID: 20235866. Clayton, E., Smith, M., Fullerton, S., Burke, W., McCarty, C., Koenig, B., McGuire, A. L., Beskow, L. M., Dressler, L., Lemke, A., Ramos, E. M., & Rodriguez, L. (2010). Confronting real time ethical, legal and social issues in the eMERGE (Electronic Medical Records and Genomics) Consortium. Genetics in Medicine . Aug 20. [Epub ahead of print]. PMID: 20733502

International Cancer Genome Consortium. (including Lynn G. Dressler, Ethics and Policy Committee).

(2010). International network of cancer genome projects. Nature. 464(7291), 993-998. PMID:

20393554. Garber, J. E., Halabi, S., Tolaney, S. M., Kaplan, E., Archer, L., Atkins, J. N., Edge, S., Shapiro, C. L., Dressler, L., Paskett, E. M., Kimmick, G., Orcutt, J., Scalzo, A., Winer, E., Levine, E., Rotche, R., Shahab, N., & Berliner, N.. for the Cancer and Leukemia Group B. (2010). Factor V leiden mutation and the risk of thromboembolic events in women receiving adjuvant tamoxifen for breast cancer: Results from CALGB 9872. Journal of the National Cancer Institute 102(13), 942-9. PMID: 20554945. Dressler, L. G. & Terry, S. (2009). How will GINA influence participation in pharmacogenomic research and clinical testing? Clinical Pharmacology and Therapeutics, 86(5), 472–475. PMID: 19844223. Dressler, L. G. (2009). Disclosure of research results from cancer genomic studies: State of the science. Clinical Cancer Research, 15(13), 4270-4276. Epub 2009 Jun 23. PMID: 19549775. Harris, L. N., Broadwater, G., Abu-Khalaf, M., Cowan, D., Thor, A. D., Budman, D., Cirrincione, C. T., Berry, D. A., Winer, E. P., Hudis, C. A., Hayes, D. F., Friedman, P., Ellis, M., & Dressler, L. (2009). Topoisomerase II amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin and fluorouracil therapy in HER2-amplified early breast cancer: Results of CALGB 8541/150013. Journal of Clinical Oncology, 27 (21), 3430-3436. PMID: 19470942. Muss, H. B., Berry, D. A., Cirrincione, C. T., Theodoulou, M., Mauer, A. M., Kornblith, A. B., Partridge, A. H., Dressler, L. G., Cohen, H. J., Becker, H. P., Kartcheske, P. A., Wheeler, J. D., Perez, E. A., Wolff, A. C., Gralow, J. R., Burstein, H. J., Mahmood, A. A., Magrinat, G., Parker, B. A., Hart, R. D., Grenier, D., Norton, L., Hudis, C. A., Winer, E. P., & CALGB Investigators. (2009). Adjuvant chemotherapy with standard regimens is superior to capecitabine in older women with early stage breast cancer. The New England Journal of Medicine, 360 (20), 2055-2065. PMID: 19439741.

LYNN G. DRESSLER CURRICULUM VITAE

8

Livasy C, Dressler LG et al. (2009). Biomarkers associated with pathologic complete response to neoadjuvant chemotherapy in women with locally advance breast cancer: restuls for the I-SPY TRIAL (CALGB 150007/150012 and ACRIN 6657). Cancer Research.69, 330s-331s. DiGiovanna, M. P., Stern, D. L., Edgerton, S., Broadwater, G., Dressler, L. G., Budman, D. R., Henderson, I. C., Thor, A. D., Norton, L., Liu, E. T., Muss, H. B., Berry, D. A., & Hayes, D. F. (2008). Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: Study 8541 from the Cancer and Leukemia Group B. Journal of Clinical Oncology, 26(14), 2364-2372. Epub 2008 Apr 7. PMID: 18390970. Millikan, R. C., Newman, B., Tse, C. K., Moorman, P. G., Conway, K., Dressler, L. G., Smith, L. V., Labbok, M. H., Geradts, J., Bensen, J. T., Jackson, S., Nyante, S., Livasy, C., Carey, L., Earp, H. S., & Perou, C. M. (2008). Epidemiology of basal-like breast cancer. Breast Cancer Research and Treatment, 109 (1), 123-139. Epub 2007 Jun 20. PMID: 17578664. Hayes, D. F., Thor, A. D., Dressler, L. G., Weaver, D., Edgerton, S., Cowan, D., Broadwater, G., Goldstein, L. J., Martino, S., Ingle, J. N., Henderson, I. C., Norton, L., Winer, E. P., Hudis, C. A., Ellsi, M. J., & Berry, D. (2007). HER2 and response to paclitaxel in node-positive breast cancer. The New England Journal of Medicine, 357(15), 1496-1506. PMID: 17928597.

Dressler, L. G. (2007). Biospecimen “ownership” counterpoint. Cancer Epidemiology, Biomarkers, and Prevention, 16(2), 190-191. PMID:17301248.

Dressler, L. G. & Juengst, E. (2006). Thresholds and boundaries in the disclosure of individual genetic research results. The American Journal of Bioethics, 6(6), 18-20. PMID: 17085396.

Jewell, S. D., Monovich, L. C., Edgerton, S., Schilksy, R., & Dressler, L. (2006). Biospecimen banking, standardization and lessons learned from the Cancer and Leukemia Group B Pathology Coordinating Office. Seminars in Breast Disease, 8(2), 93-99.

Kelly H, Kimmick G, Dees EC, Collichio F, Gatti L, Sawyer L, Ivanova A, Dressler L, Graham ML, Carey LA. (2006). Response and cardiac toxicity of trastuzumab given in conjunction with weekly paclitaxel after doxorubicin/cyclophosphamide. Clin Breast Cancer 7(3), 237-243. PMID: 16942640. Harris, L. N., Broadwater, G., Lin, N. U., Miron, A., Schnitt S., Cowan, D., Lara, J., Bleiweiss, I., Berry, D., Ellis, M., Hayes, D., Winer, E., & Dressler, L. (2006). Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: Results from CALGB 9342. Breast Cancer Research, 8(6), R66. PMID: 17129383.

Carey, L.A., Perou, C.M., Livasy, C.A., Dressler, L.G., Cowan, D., Conway, K., Karaca, G., Troester, M.A., Tse, C.K., Edmiston, S., Deming, S.L., Geradts, J., Cheang, M.C., Nielsen, T.O., Moorman, P.G., Earp, H.S., & Millikan, R.C. (2006). Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. Journal of the American Medical Association, 295(21), 2492-2502. PMID: 16757721.

Rincon, M., Broadwater, G., Harris, L., Crocker, A., Weaver, D., Dressler, L., Berry, D., Sutton, L., Michaelson, R., Messino, M., Kirshner, J., Fleming, G., WIner, E., Hudis, C., Appel, S., Norton, L., Muss, H., & Cancer and Leukemia Group B. (2006). Interleukin-6, multidrug resistance protein-1 expression

LYNN G. DRESSLER CURRICULUM VITAE

9

and response to paclitaxel in women with metastatic breast cancer: Results of the Cancer and Leukemia Group B trial 159806. Breast Cancer Research and Treatment, 100(3), 301-308. PMID: 16773437.

Hu, Z., Fan, C., Oh, D. S., Marron, J. S., He, X., Qaqish, B.F., Livasy, C., Carey, L.A., Reynolds, E., Dressler, L., Nobel, A., Parker, J., Ewend, M. G., Sawyer, L. R., Wu, J., Liu, Y., Nanda, R., Tretiakova, M., Orrico, A. R., Dreher, D., Palazzo, J. P., Perreard, L., Nelson, E., Mone, M., Hansen, H., Mullins, M., Quackenbush, J. F., Ellis, M. J., Olopade, O. I., Bernard, P. S., & Perou, C. M. (2006). The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics, 7, 96. PMID: 16643655.

Lark, A., Livasy, C., Dressler, L., Moore, D., Millikan, R., Geradts, J., Iacocca, M., Cowan, D., Little, D., Craven, R., & Cance, W. (2005). High focal adhesion kinase expression in invasive breast carcinomas is associated with an aggressive phenotype. Modern Pathology, 18(10), 1289-1294. PMID: 15861214.

Dressler, L. G., Berry, D. A., Broadwater, G., Cowan, D., Cox, K., Griffin, S., Miller, A., Tse, J., Novotny, D., Persons, D. L., Barcos, M., Henderson, I. C., Liu, E. T., Thor, A., Budman, D., Muss, H., Norton, L., & Hayes, D. F. (2005). Comparison of HER2 status by fluorescent in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. Journal of Clinical Oncology, 23 (19), 4287-4297. PMID: 15994142.

Dressler, L. (2005). Human specimens, cancer research and drug development: How science policy can promote progress and protect research participants. Invited Background Paper. National Cancer Advisory Board of the Institutes of Medicine (IOM). Available at: http://www.iom.edu/Object.File/Master/26/207/IOM_fnl.pdf.

Nielsen, T. O., Hsu, F. D., Jensen, K., Cheang, M., Karaca, G., Hu, Z., Hernandez-Boussard, T., Livasy, C., Cowan, D., Dressler, L., Akslen, L. A., Ragaz, J., Gown, A. M., Gilks, C. B., van de Rijn, M., & Perou, C. M. (2004). Immunohistochemical and clinical characterization of a basal-like subtype of invasive breast carcinoma. Clinical Cancer Research, 10 (16), 5367-5374. PMID: 15328174.

Lightfoot, H. M., Lark, A., Livasy, C., Moore, D., Cowan, D., Dressler, L., Craven, R. J., & Cance, W. (2004). Upregulation of focal adhesion kinase (FAK) expression in ductal carcinoma in situ (DCIS) is an early even breast tumorigenesis. Breast Cancer Research and Treatment, 88 (2), 109-116. PMID: 15564794.

Usary, J., Llaca, V., Karaca, G., Presswala, S., Karaca, M., He, X., Langerod, A., Karesen, R., Oh, D. S., Dressler, L. G., Lonning, P. E., Strausberg, R. L., Chanock, S., Borresen-Dale, A. L., & Perou, C. M. (2004). Mutation of GATA3 in human breast tumors. Oncogene, 23 (46), 7669-7678. PMID: 15361840. Chung, C. H., Parker, J., Karaca, G., Wu, J., Funkhouser, W. K., Moore, D., Xiang, D., Shockley. W. W., Weissler, M. C., Dressler, L., Shores C. G., Yarbrough, W. G., & Perou, C. M. (2004). Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell, 5 (5), 489-500. PMID: 15144956.

LYNN G. DRESSLER CURRICULUM VITAE

10

Millikan, R., Eaton, A., Worley, K., Biscocho, L., Hodgson, E., Hunag, W., Geradts, J., Iacocca, M., Cowan, D., Conway, K., & Dressler L. (2003). HER2 codon 655 polymorphism and risk of breast cancer in African American and whites. Breast Cancer Research and Treatment, 79 (3), 355-364. PMID: 12846420.

Furberg, H., Millikan, R. C., Geradts, J., Gammon, M. D., Dressler, L. G., Ambrosone, C. B., & Newman, B. (2003). Reproductive factors in relation to breast cancer characterized by p53 protein expression (United States). Cancer Causes and Control, 14 (7), 609-618. PMID: 14575358.

Stitzenberg, K. B., Calvo, B. F., Lacocca, M. F., Neelon, B. H., Sansbury, L., Dressler, L., & Ollila, D. W. (2002). Cytokeratin immunohistochemical validation of the sentinel node hypothesis in breast cancer patients. American Journal of Clinical Pathology, 117 (5), 729-737. PMID: 12090421.

Conway, K., Edmiston, S., Cui, L., Drouin, S., Pang, J., Tse, C. K., Geradts, J., Dressler, L., Liu, E., Millikan, R., & Newman, B. (2002). The prevalence and spectrum of p53 mutations implicates smoking in breast cancer development. Cancer Research, 62 (7), 1987-1995. PMID: 11929815.

Schilsky, R., Dressler, L., Bucci, D., Monovitch, L., Jewell, S., Suster, S., Caliguiri, M., Kantoff, P., & Compton, C. (2002). Cooperative group tissue bank as research resources: The Cancer and Leukemia Group B tissue repositories. Clinical Cancer Research, 8 (5), 943-948. PMID: 12006505.

Amador-Zarco, J. J., Maro-Tiscareno, A., Sangri-Pinto, A. G., Braun-Roth, G., Dressler, L. G., Kulwichit, W., Van Dyke, T., & Calderon-Garciduenas, L. (2002). Nasal squamous cell carcinoma in a child. Journal of Otolaryngology, 31 (1). 45-49. PMID: 11881772.

Furberg, H., Millikan, R., Dressler, L., Newman, B., & Geradts, J. (2001). Tumor characteristics in African American and white women. Breast Cancer Research and Treatment, 68 (1) 33-43. PMID: 11678307. Page, D. L., Gray, R., Allred, D. C., Dressler, L. G., Hatfield, A. K., Martino, S., Robert, N. J., & Wood, W. C. (2001). Prediction of node-negative breast cancer outcome by histologic grading and S-phase analysis by flow cytometry: an Eastern Cooperative Oncology Group study (2192). American Journal of Clinical Oncology, 24 (1), 10-18. PMID: 11232942.

Berry, D. A., Muss, H. B., Thor, A. D., Dressler, L., Liu, E. T., Broadwater, G., Budman, D. R., Henderson, I. C., Barcos, M., Hayes, D., & Norton, L. (2000). HER2/neu and p53 expression versus tamoxifen resistance in estrogen receptor positive node positive breast cancer. Journal of Clinical Oncology, 18 (20), 3471-3479. PMID: 11032587. Dressler, L. G. & Thor, A. D. (2000). HER2 testing: Laboratory, technical and clinical issues. Breast Disease, 11, 77-87. PMID: 15687594.

Simpson, J. F., Gray, R., Dressler, L.G., Cobau, C. D., Falkson, C. I., Gilchrist, K. W., Pandya, K. J., Page, D. L., & Robert, N. J. (2000). Prognostic value of the histologic grade and proliferative activity in axillary node positive breast cancer: Results for the Eastern Cooperative Oncology Group Protocol EST4189. Journal of Clinical Oncology, 18, 2059-2069. PMID: 10811671.

Page, D. L., Allred, D. C., Dressler, L. G., Gray, R., Hayes, D. F., Morrow, M., Norton, L., Sylvester, J., & Thor, A. D. (2000). Prognostic value of the histologic grade and proliferative activity in axillary node positive breast cancer: Results from the Eastern Cooperative Oncology Group Companion Study, EST 4189. Journal of Clinical Oncology, 18 (10), 2059-2069. PMID: 10811671.

LYNN G. DRESSLER CURRICULUM VITAE

11

Page, D. L., Allred, D. C., Dressler, L. G., Gray, R., Hayes, D. F., Morrow, M., Norton, L., Sylvester, J., Thor, A. D., & Wood, W. C. (1999). Breast cancer working group report: AJCC Prognostic Factors Consensus Conference Report. Cancer, 5-9.

Dressler, L. G., Geradts, J., Burroughs, M., Cowan, D., Millikan, R. C., & Newman B. (1999). Policy guidelines for the utilization of formalin- fixed, paraffin-embedded tissue sections. the UNC SPORE experience. University of North Carolina Specialized Program of Research Excellence. Breast Cancer Research and Treatment, 58 (1), 31-39. PMID: 10634516.

Millikan, R. C., Kornblith, A. B., McIntyre, O. R., Berry, D., Broadwater, G., Sandler, D., Karas, K., Dressler, L. G., Gross, L., Collyar, D., & Schilsky, R. (1998). Genetic testing in breast cancer cooperative clinical trials: Barriers and opportunities. Cancer Therapeutics, 1, 95-99.

Dressler, L. G. (1998). Genetic testing for the BRCA1 gene and the need for protection from discrimination: an evolving legislative and social issue. Breast Disease, 10 (1,2), 127-135. PMID: 15687555.

Wong, G., Stidley, C., Dressler, L., Castillo, M., Crooks, L., & Bartow, S. (1996). Predictive value of flow cytometric analysis in DNA contents in patients with locally advanced head and neck carcinoma. Journal of Laryngology and Otology, 110 (3), 243-248. PMID: 8730360.

Millikan, R., Dressler, L., Geradts, J., & Graham, M. (1995). The need for epidemiologic studies of in-situ carcinoma of the breast. Breast Cancer Research and Treatment, 35 (1), 65-77. PMID: 7612906.

Mansour, E. G., Ravdin, P. M., & Dressler, L. G. (1994). Prognostic factors in early breast cancer. Cancer, 74 (1 Suppl), 381-400. PMID: 8004612. Dressler, L. G., & Seamer, L. C. (1994). Controls, standards, and histogram interpretation in DNA flow cytometry. Methods Cell Biol, 41, 241-262. PMID: 7861966. Dressler, L. G. (1993). DNA flow cytometry measurements as surrogate endpoints in breast cancer chemoprevention: Clinical, biological and quality control considerations. Journal of Cellular Biochemistry. Supplement, 17G, 212-218. PMID: 8007701.

Kesterson, L., Shelton, C., Dressler, L., & Berliner, K. I. (1993). Clinical behavior of acoustic tumors: A flow cytometric analysis. Archives of Otolaryngology-Head and Neck Surgery, 119 (3), 269 -271. PMID: 8435163.

Dressler, L. G., Duncan, M. H., Varsa, E. E., McConnell, T. S. (1993). DNA content measurement can be obtained using archival material for DNA flow cytometry: A comparison with cytogenetic analysis in 56 pediatric solid tumors. Cancer, 72 (6), 2033-2041. PMID: 8395970.

Dressler, L. G. (1992). Are DNA flow cytometry measurements providing useful information in the management of the node negative breast cancer patient? Cancer Investigation, 10 (5), 477-486. PMID: 1393694.

Clark, G. M., Mathieu, M. C., Owens, M. A., Dressler, L. G., Eudey, L., Tormey, D. T., Osborne, C. K., Gilchrist, K. W., Mansour, E. G., Abeloff, M. D., & McGuire, W. L. (1992). Prognostic significance of S

LYNN G. DRESSLER CURRICULUM VITAE

12

phase fraction in good risk node negative breast cancer patients. Journal of Clinical Oncology, 10 (3), 428-432. PMID: 1740681.

Dressler, L. G., Eudey, L., Gray, R., Tormey, D., Gilchrist, K., McGuire, W. L., Clark, G., Osborne, C. K., Mansour, E., Abeloff, M. (1992) Prognostic potential of DNA flow cytometry measurements in node negative breast cancer patients: Preliminary analysis of an intergroup study (INT 0076). Journal of the National Cancer Institute,. Monographs, (11), 167-172. PMID: 1627424.

Varsa, L., McConnell, T., Dressler, L. G., & Duncan, H. (1989). Atypical congenital mesoblastic nephroma. Report of a case with karyotypic and flow cytometric analysis. Archives of Pathology and Laboratory Medicine, 113 (9), 1078-1080. PMID: 2549909.

Longacre, T., Foucar, K., Crago, S., Chen, I. M., Griffith, B., Dressler, L. G., McConnell, T., Duncan, M., & Gribble, T. (1989). Hematogones: a multiparameter analysis of bone marrow precursor cells. Blood, 73 (2), 543-552. PMID: 2917189.

Kerrigan, D., Foucar, K., & Dressler, L. G. (1989). High-grade non-Hodgkins lymphoma relapsing as low-grade follicular lymphoma: so called downgraded lymphoma. American Journal of Hematology, 30 (1), 36-43. PMID: 2535611.

Clark, G. M., Dressler, L. G., Owens, M. A., Pounds, G., Oldaker, T., & McGuire, W. L. (1989). Prediction of relapse or survival in patients with node-negative breast by DNA flow cytometry. New England Journal of Medicine, 320 (10), 627-633. PMID: 2918874.

Dressler, L. G., Seamer, L., Owens, M. A., Clark, G. M., & McGuire, W. L. (1988). DNA flow cytometry and prognostic factors in 1331 frozen breast cancer specimens. Cancer, 61 (3), 420-427. PMID: 3338012.

Dressler, L. G., Seamer, L., Owens, M. A., Clark, G. M., & McGuire, W. L. (1987). Evaluation of a modeling system for S-phase estimation in breast cancer by flow cytometry. Cancer Research, 47 (20), 5294-5302. PMID: 3652035.

Merkel, D. E., Dressler, L. G., & McGuire, W. L. (1987). Flow cytometry, cellular DNA content, and prognosis in human malignancy. Journal of Clinical Oncology, 5 (10), 1690-1703. PMID: 3309200.

Dressler, L. G., Ramzy, I., Sledge, G. W. Jr., & McGuire, W. L. (1986). A new marker of maturation in the cervix: the estrogen regulated 24K protein. Obstetrics and Gynecology, 68 (6), 825-831. PMID: 3537878.

Edwards, D. P., Grzyb, K. T., Dressler, L. G., Mansel, R. E., Zava, D. T., Sledge, G. W., & McGuire, W. L. (1986). Monoclonal antibody identification and characterization of a Mr 43,000 membrane glycoprotein associated with human breast cancer. Cancer Research, 46 (3), 1306-1317. PMID: 3510721. Edwards, D. P., Dressler, L. G., Zava, D. T., & McGuire, W. L. (1986). Monoclonal antibody characterization of a tumor-associated breast cancer antigen. Prog Clin Biol Res, 204, 71-88. PMID: 2421350.

LYNN G. DRESSLER CURRICULUM VITAE

13

McGuire, W. L., Dressler, L. G., Sledge, G. W., Ramzy, I., & Ciocca, D. R. (1986). An estrogen regulated protein in normal and malignant endometrium. Journal of Steroid Biochemistry, 24 (1), 155-159. PMID: 3702402.

McGuire, W. L., Clark, G. M., Dressler, L. G., & Owens, M. A. (1986). Role of steroid hormone receptors as prognostic factors in primary breast cancer. NCI Monoqraphs (1), 19-23. PMID: 3774012.

McGuire, W. L., & Dressler, L. G. (1985). Emerging impact of flow cytometry in predicting recurrence and survival in breast cancer patients. Journal of the National Cancer Institute, 75 (3), 405-410. PMID: 3861896.

Lathan, B., Edwards, D. P., Dressler, L. G., Von Hoff, D. D., & McGuire, W. L. (1985). Immunologic detection of Chinese hamster ovary cells expressing a multidrug resistance phenotype. Cancer Research, 45 (10), 5064-5069. PMID: 2862990.

Sledge, G. W., Ramzy, I., Dressler, L. G., Dorr, F. A., Adams, D. J., & McGuire, W. L. (1985). Presence of an estrogen-regulated protein in endometrial cancer. Obstetrics and Gynecology, 66 (3), 423-427. PMID: 3895080.

Alfano, J., Dressler, L. G., & Brownie, A. C. (1985). Immunoreactive ACTH and gamma-MSH in rat plasma during early stages of adrenal regeneration. American Journal of Physiology, 248 (4 Pt 1), 471-474. PMID: 2984942.

Ip, M. M., Milholland, R. J., Shea, W. K., & Dressler, L. G. (1985). Binding of the gulcocorticioid receptor complex to the nucleosomal core in the P1798 mouse lymphosarcoma. Molecular and Cellular Endocrinology, 41 (1), 45-49. PMID: 3924686.

Refereed Abstracts (Oral/Poster Presentations): Submitted: Lynn G. Dressler , Nikolajs Zeps, Allison Deal, Janell Markey and Bartha Knoppers on behalf of the Ethics and Policy Working Group of the International Cancer Genome Consortium (ICGC). Return of individual results from cancer genomic research: genomic researcher experiences and institutional practices. American Society of Clinical Oncology (ASCO). May 2014, Chicago. Completed: Lynn Dressler, Jai Patel, Allison Deal, Janell Markey, Howard McLeod and Marcia Van Riper. Cancer Pharmacogenomic Testing, Clinician Adoption and Patient Benefit. Clinical Genomics for Cancer Management. Cambridge Healthtech Institute. Boston. September 24, 2013. (Oral presentation) Lynn Dressler. Addressing the Ethical, Legal, Social and Policy Issues related to integrating personalized medicine into routine clinical care. 5th Annual Personalized Medicine Conference. The Emerging Practice of Personalized Medicine. Boston. October 21, 2013. Lynn Dressler, Allison M Deal, , Dee Watson, Donna Hollis, Kouros Owzar, Kathleen Donohue, Paula N. Friedman, Mark J. Ratain, and Howard L. McLeod. Participation in cancer pharmacogenomic studies: A

LYNN G. DRESSLER CURRICULUM VITAE

14

study of 8,456 patients registered to clinical trials in the Cancer and Leukemia Group B (CALGB). Oral presentation. American Society of Clinical Oncology Annual Meeting. May 30- June 4, 2013, Chicago, Illinois. Benyam Muluneh, Maurice Alexander, Allison Mary Deal, Janell Marker, Jennifer Neal, Stephen A Bernard, John Valgus, Lynn G. Dressler. Prospective evaluation of perceived barriers to medication adherence by patients on oral antineoplastics. ASCO abstract 91616. (Poster) June, 2012. Chicago, Illinois. Lynn G. Dressler , Janell Markey, Allison Deal and Bartha Knoppers on behalf of the Ethics and Policy Working Group of the International Cancer Genome Consortium (ICGC). Return of individual results from cancer genomic research: ICGC researcher experiences and institutional practices. 6th Annual Meeting of the International Cancer Genome Consortium (ICGC). March, 2012. Cannes, France.(Oral presentation at HOT TOPICS session) Andrea N. Yuen, Pharm.D. Candidate; Jeffrey M. Peppercorn, M.D.; Lynn G. Dressler, Dr.PH. W.K. Chiu, M.S.; Christine M. Walko, Pharm.D; P. Rubin, M.D.; O. Olajide, M.D.; R. Raab, M.D.; D. Carrizosa, M.D.; S. Corso, M.D.; G.Schwartz, M.D.; Howard L. McLeod, Pharm.D.; Lisa A. Carey, M.D.; William J. Irvin, Jr, M.D. Breast cancer patient understanding and knowledge of pharmacogenomic testing in Lineberger Comprehensive Cancer Center trial 0801. ACCP Meeting. 2011, (Poster). Dressler LG and Bartha Knoppers. Return of individual research results from cancer genomic studies: researcher experiences and institutional practices. The Cancer Genome Atlas (TCGA) Study First Annual Meeting, November 2011. Washington DC. (Poster) Dressler LG. Return of individual research results. Handling diagnostic discrepancies and incidental findings in Biospecimen Research. Panel Discussion. Ethical, Legal, Social Implications of Genomic Research (ELSI)Congress, 2011. April, 2011. (Oral Presentation) Dressler, LG, Deal A, McLeod H, Van Riper et al. Cancer pharmacogenomic testing, clinician adoption and patient benefit.. Ethical, Legal, Social Implications of Genomic Research (ELSI)Congress, 2011. April, 2011. (Oral Presentation). Dressler LG and McLeod H. Return of Individual Research results from pharmacogenomic versus disease susceptibility studies. Ethical, Legal, Social Implications of Genomic Research (ELSI)Congress, 2011. April, 2011.(Oral Presentation) N. T. Brewer, C. M. Walko, W. K. Chiu, L. G. Dressler, A. Yuen, P. Rubin, O. A. Olajide, S. G. Moore, R. E. Raab, D. R. Carrizosa, S. W. Corso, G. Schwartz, J. M. Peppercorn, H. L. McLeod, L. A. Carey, W. J. Irvin. Patients’ understanding of how genotype variation affects benefits of tamoxifen therapy for breast cancer. J Clin Oncol 29:2011 (Suppl; abstract 6029). 2011 American Society of Clinical Oncology Meeting. (Poster) Dressler LG: “ Return of individual research results from genomic studies: Perspectives of IRBs. “Cold Spring Harbor Symposium on Pharmacogenomics and Personalized Medicine. November, 18th, 2010. Cold Spring Harbor, NY. (Oral presentation)

LYNN G. DRESSLER CURRICULUM VITAE

15

Dressler, LG. “The Need to Incentivize Post Marketing Improvements in Pharmacogenonic Tests: the HER2 story in breast cancer. “Genomics and Ethics 13th Annual Meeting. Breckenridge, Co. July, 2009. (Oral Presentation) Dressler LG, Ponsaran R, Trinidad S, Gerson N, Lewis S, Markey J, Skinner D, Press N and Weisner G for the Genetics Research Review and Issues Project (GRIPP). Disclosure of Genetic Research Results: Perspectives of IRB Members and Staff. Moderated Discussion. Annual Meeting of Public Responsibility of Medical Research (Advancing Ethical Research Conference), November 14-15, 2009.(Oral Poster Discussion). Dressler LG. Research Regulators’ Concerns with Access and Use of Open-Source Genetic Research Data.” ASHG Social Policy Panel: DNA as a Unique Identifier: Privacy, Trust, and the Future of Genomic Biorepositories. October, 2007: American Society of Human Genetics (ASHG) Annual Meeting. (Oral Presentation) D. F. Hayes, A. Thor, L. Dressler, D. Weaver, G. Broadwater, L. Goldstein, S. Martino, J. Ingle, I. C. Henderson, D. Berry. HER2 predicts benefit from adjuvant paclitaxel after AC in node-positive breast cancer: CALGB 9344. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 510 (Oral Presentation) Dressler LG. Guiding Principles of Conduct for Using Human Specimens in Genetic and Translational Research: Findings from a 10 year retrospective study. PRIMR/ARENA Annual Meeting. Washington DC, November, 2006. (Oral Presentation) Dressler LG. Ethical Issues and Policy Recommendations for the Use of Human Specimens in Genetic Research: A 10 yr Retrospective Study. Fondation Brocher. Value and Risks of Genetic Data Collections. Platform Presentation Geneva, Switzerland, November 10-11, 2005. Dressler LG. Use of Stored Specimens in Research: Challenges and Solutions. Oral Presentation. (ISBER) International Society of Biological and Environmental Repositories Annual Meeting. Seattle, WA. May 1-4, 2005. Seidman A, Broadwater G, Carny WP, Dressler LG, Berry D, Norton L, Hudis CA, Winer E, Ellis MJ, Harris LN. Serum HER2 extracellular domain (ECD) levels and efficacy of weekly (W) or every 3-weekly (q3W) paclitaxel (P) with or without trastuzumab (T) in patients (pts) with metastatic breast cancer (MBC): CALGB 150002/9840. Poster Discussion. American Society of Clinical Oncology (ASCO). May 15-17, 2005. Garber JE, Halabi S, Kaplan EB, Edge S, Dressler L, Paskett E, Berliner N. Factor V Leiden (FVL) Mutations and Thromboembolic Events (TE) In Women With Breast Cancer In Adjuvant Tamoxifen. American Society of Clinical Oncology (ASCO). May 15-17, 2005. Carey L, Harden A, Livasy C, Sawyer L, Moore D, Little D, Cowan D, Dees C, Collichio F, Graham M, Dressler L. HER2, TopoII and p53 and Response to Sequential Anthracycline then Taxane Neoadjuvant Therapy in Primary Breast Cancer. San Antonio Breast Cancer Symposium. Breast Cancer Research and Treatment 88(1):S52, Abstract 1033. 2004. Seidman AD, Berry D, Cirrincione C, Harris L, Dressler L, Muss H, Naughton M, Norton L, Winer E, Hudis C. CALGB 9840: Phase III study of weekly (W) paclitaxel (P) via 1-hour (h) infusion versus standard (S) 3h

LYNN G. DRESSLER CURRICULUM VITAE

16

infusion every third week in the treatment of metastatic breast ancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC. Late-breaking abstract #512. Oral Presentation. ASCO. New Orleans, June 5-8, 2004. Dressler, L, Broadwater G, Berry D, Cirrincione C, Cowan D, Harris, L, Moore D, Muss H, Hayes DF, Ellis M: for the Cancer and Leukemia Group B. A comparison of two HER2 Fluorescence in situ hybridization (FISH) methods to measure HER2 amplification and Predict Outcome in Stage II Breast Cancer. Poster Discussion. ASCO. New Orleans, June 5-8, 2004. L Harris, L Dressler, D Cowan, D. Berry, C Cirrincione, G Broadwater, P Friedman, H Muss, D Hayes, M Ellis.

Comparison of HER-2 and Topoisomerase II (Topo II) Amplification with Outcome after Cyclophosphamide, Doxorubicin and 5FU (CAF)-based Chemotherapy for Stage II Breast Cancer (CALGB 8541/150013). Oral Presentation. ASCO, New Orleans, June 5-8, 2004. Carey LA, Dees EC, Sawyer L, Moore DT, Dressler L, Cowan D, Harden A, Collichio F, Ollila D, Sartor C, Tsui A, Graham M. Response to Trastuzumab (Herceptin) Given with Paclitaxel (Taxol, T) Immediately Following 4AC as Initial Therapy for Primary Breast Cancer (BrCa). Breast Cancer Res Treat 76: 424a (2002). M. Gaudet, N. Simonsen, L. Dressler, S. London, A. Miller, L. Arab. Intakes of selected fruits and vegetables and their associations with tumor p53 expression among breast cancer cases. SER/Congress of Epidemiology Meeting. June. 2001. McIntyre, OR, Millikan RC, Kornblith AB, Berry D, Broadwater G, Sandler D, Karas K, Dressler, LG, Gross L, Collyar D and Schilsky R. Genetic testing in breast cancer cooperative clinical trials: barriers and opportunities. Dept of Defense, Army Materiel Command. National Symposium on Breast Cancer. November, 1997. Dressler LG, Geradts J, Gonzalez P, Sprouse R, Burroughs M amd M Graham. Evaluation of Cell Response to Pre-Surgical Chemotherapy by DNA Flow Cytometry. Platform Presentation. Cell Kinetics Meeting. Cell Proliferation, 1995. Dressler LG, Geradts J, Gonzalez P and Graham M. Characterization of cellular response to neoadjuvant chemotherapy by DNA flow cytometry. 17th Annual Breast Cancer Symposium. Breast Cancer Research and Treatment. Vol 32. Supplement.Abstract #99. p53. 1994. Dressler LG, Varsa E, Duncan M, Bartow S, Allgood G, Baca P, Seamer L, Woodward L and McConnell T: Comparison of ploidy by flow cytometry and G-banded cytogenetic analysis in solid tumors from 56 pediatric patients. 4th International Workshop on Chromosomes in Solid Tumors, Tucson, Arizona, February 24-26, 1991. Kesterson L, Shelton C, Dressler LG, Seamer L, Benzel E: Flow cytometric analysis of archival paraffin block tissue of acoustic neuromas, American Association of Neurological Surgeons, April 20-25, 1991, New Orleans. Kesterson L, Shelton C, Dressler LG, Seamer L, Benzel E: Flow cytometric DNA ploidy and S-phase fraction analysis of archival paraffin block acoustic neuromas, The American Laryngological, Rhinological and Otological Society, January 11, 1991.

LYNN G. DRESSLER CURRICULUM VITAE

17

Smith A, Dragun M, Dressler LG, Bartow S: Flow cytometric Sphase analysis in radical nephrectomy patients, American Urological Society, Toronto, 1991. Dressler LG, Clark GM, Owens MA, Pounds G, Oldaker T and McGulre WL: DNA f low cytometry is an important predictor of tumor recurrence in the node negative breast cancer patient. Proceedings of the American College of Physicians, Albuquerque, New Mexico, 1987. Clark GM, Owens MA, Dressler LG, et al: A new model for estimating S-phase fraction in node negative breast cancer patients. Proceedings for the American Association of Cancer Research 1990; 31:1984. Dressler LG, Eudey L, Gray R, Tormey D, McGuire W, Osborne C, Gilchrist K, Mansour E and Abeloff M: DNA flow cytometry measurements are important predictors of time to recurrence in node negative breast cancer patients: an Eastern Cooperative Group (ECOG) Intergroup Study (EST) 7186, SWOG 8696, INT0076, platform presentation. Proceedings of the American Association of Clinical Oncology (ASCO), Vol. 9, Abstract #81, p. 22. May 20-22, 1990. Dressler LG, Gray R, Tormey D, McGuire W, Osborne C, Gilchrist K, Mansour E and Abeloff M: Prediction of recurrence and therapy response in the node negative breast cancer patient by DNA flow cytometry: An Eastern Cooperative Oncology Group Intergroup Study (EST 7186; SWOG 8696; INT0076). Platform presentation, 12th Annual San Antonio Breast Cancer Symposium, December 8-9, 1989, San Antonio, Texas, Breast Cancer Research and Treatment, 1989. Dressler LG, Bartow S, Ford E, Seamer L, Whittlinger D and Stidley C: Quality DNA flow cytometry results can be obtained using paraffin block specimens of solid tumors. Proceedings of the International Academy of Pathology (IAP), Boston, Mass., March, 1990. Smith AY, Huang WL, Dressler LG, Stidley C, Lowe B: The prognostic value of DNA flow cytometry in Stage A adenocarcinoma of the prostate. Proceedings of American Urologic Association, Dallas, Texas, 1989. Clark GM, Dressler LG, Owens MA, and McGuire WL: Flow cytometry identifies a group of node negative breast cancer patients with low risk of recurrence. 11th Annual Breast Cancer Symposium, San Antonio, Texas, December, 1988. William C, Elias L, Griffith B, Dressler LG, Erickson-Ford L, Head D, Kopecky K, Stock-Novak D, Weick T, Grever M: Identification of biological parameters distinguishing primary resistant acute myeloid leukemia patients: a Southwest Oncology Group study. Proceedings of ASH, 1988. Seamer L, Dressler LG, Schimke R: Comparison of S phase estimation using BrdU incorporation vs. a paral/para2 modeling system. Proceedings of the XIIII International Meeting of the Society for Analytical Cytology, Suppl. 2, Breckenridge, Colorado, 1988. Longacre T, Dressler LG and Willman C: Differential expansion of myeloid lineage tyrosine kinase genes in acute myeloid leukemia. Proceedings of the International Academy of Pathology, Washington, D.C. , 1988. Clark GM, Dressler LG, Owens MA, Pounds G, Oldaker T and McGuire WL: DNA flow cytometry predicts time to recurrence and survival in 606 axillary node negative breast cancer patients. Proceedings of ASCO, New Orleans, Louisiana, 1988.

LYNN G. DRESSLER CURRICULUM VITAE

18

Owens MA, Dressler LG, Clark C, Pounds H, Oldaker T, and McGuire WL: Ploidy and S phase predict relapse in node negative breast cancer-patients. Proceedings of the XII International Meeting of the Society of Analytical Cytology, Cambridge, Suppl. 1, 1987. Dressler LG, Clark G, Owens M, Pounds G: DNA flow cytometry predicts for relapse in node negative breast cancer patients. Proceedings of ASCO, Los Angeles, CA, 1987. Deacon T, Shenkenberg T, Dressler LG, Von Hoff DD and McGuire WL: Drug resistance of the expression of Pglycoprotein in CHO cell line. Proceedings of the National Student Research Forum, Galveston, Texas, May, 1986. Shenkenberg TD, Dressler LG and McGuire WL: Flow cytometry and monoclonal antibodies measure estrogen and progesterone receptor in breast cancer patients. Proceedings of Annual Endocrine Society Meetings, Anaheim, California, June, 1986. Ramzy I, Dressler LG, Schantz HD, McGuire WL, Sledge G: Estrogen regulated 24K protein markers for cervical epithelial maturation: immunohistochemical and immunocytochemical study. Proceedings of the American Society of Cytology, Detroit, Michigan, October, 1986. Owens MA, Dressler LG, Seamer L, Pounds GW and McGuire WL: New models of DNA analysis for identification of high risk breast cancer patients. Proceedings of AACR 27:32. 1986. Shenkenberg T, Deacon T, Dressler LG, Von Hoff DD and McGuire WL: Increase in drug resistance in CHO cells by enriching for P-glycoprotein by flow cytometry. Proceedings of AACR 27:261. 1986. Shenkenberg T, Deacon T, Dressler LG, Von Hoff DD and McGuire WL: Estrogen receptor measurement by flow cytometry; multiparameter analysis should identify high risk breast cancer patients. Proceedings of ASCO 5:10. 1986. Dressler LG, Owens M, Seamer L and McGuire WL: Identifying breast cancer patients for adjuvant therapy by DNA flow cytometry and steroid receptor: a 1000 patient study. Proceedings of ASCO; 5:10. 1986. Practical experience in the DNA analysis of 1000 tumors; problems and solutions. Coulter User's Meeting, New Orleans, December 3-5, 1985. El-Ashry D, Edwards DP, Dressler LG and McGuire WL: Monoclonal antibody characterization of a breast cancer associated 43,000 dalton membrane glycoprotein. Proceedings of the 8th Annual Breast Cancer Symposium. Breast Cancer Research & Treatment 6:182. 1985. Osborne DK, Hobbs K and Dressler LG. Growth factors produced by MDA-231 human breast cancer cells do not support the growth of hormone dependent MCF-7 cells in castrated nude mice. Breast Cancer Research & Treatment ,1985. Owens M, Dressler LG, Seamer L and McGuire WL: New models of breast cancer proliferation and aneuploidy. Proceedings of the 8th Annual Breast Cancer Symposium. Breast Cancer Research & Treatment 6-183. 1985.

LYNN G. DRESSLER CURRICULUM VITAE

19

Dressler LG, Seamer L, Owens M, Srivatsa R and McGuire WL: DNA flow cytometric measurements and their relationship to clinical variables. Proceedings of the 8th Annual Breast Cancer Symposium. Breast Cancer Research & Treatment 6:166. 1985. Dressler LG, Ramzy I, Sledge GW Jr. and McGuire WL: A new marker of maturation in the cervix: the estrogen regulated 24K protein. Proceedings of ASCO, Houston, May 19-21, 1985. Invited Oral Presentations: Dressler, LG. Building a personalized genomic medicine program in a community health system: The Mission Health Experience. Institutes of Medicine Roundtable. Translating Genomic-Based Research for Health. December 04, 2013. Dressler, LG. Challenges and Opportunities in Developing and Implementing a Personalized Genomic Medicine Program at Mission Health. NIH/NHGRI Genomic Medicine Colloquium V. Bethesday MD. May 28, 2013. Dressler, LG. Personalized Medicine: changing the course of health care. Healthcare Innovation Management Certificate Program. Mission Center for Innovation. April 11, 2013. Dressler LG. What about privacy and progress in whole genome sequencing? Moderator and Discussant. Genetic Alliance Webinar. April 9, 2013. Dressler, LG. Return of research results from pharmacogenomic versus disease susceptibility studies: What’s Drugs Got to Do With IT? St Jude’s Children’s Hospital, April 1, 2013. Dressler, LG. Race disparity in participation in CALGB cancer pharmacogenomic studies. Alliance Annual Group Meeting. Health Disparities Committee. Chicago, Illinois. June 29th, 2012. Dressler, LG, Integrating cancer pharmacogenomics into clinical practice. University of North Carolina Institute of Pharmacogenomics and Individualized Therapy Seminar Series. January, 2012. Dressler LG. Returning results from biospecimen research in breast cancer: What’s the fuss all about? Translational Breast Cancer Research Consortium. NCI Consortium of Breast Cancer Advocacy Groups. Webinar presentation. September 9th, 2011. Dressler, LG. Returning individual research results from biospecimen and genomic research. Research Advocacy Network. Webinar Presentation. April 19, 2011. Dressler LG. “Integrating Science and Public Policy: Pharmacogenomics at the Clinical Interface.”IQPC 4th Biobanking Meeting. January 24-26, 2011. Dressler LG: “Ethical Issues, Clinical Cancer Trials and Use of Biosepcimens. A Research Ethics Consultation Seminar for the UNC Lineberger Comprehensive Cancer Center Protocol Office. December 10, 2010.

LYNN G. DRESSLER CURRICULUM VITAE

20

Dressler LG: “ Setting the Stage: Return of Individual Research Results from Biospecimen Research.” Workshop D20. If, When and How to Return Research Results. Public Responsibility in Medical Research (PRIMR) Annual Meeting. December 7th, 2010, San Diego, CA Dressler LG: “ Return of individual research results from genomic studies: Perspectives of IRBs. “Cold Spring Harbor Symposium on Pharmacogenomics and Personalized Medicine. November, 18th, 2010. Cold Spring Harbor, NY. Dressler LG and King NM. Addressing Ethical Dilemmas in Genomic Research: Let’s Talk. A Research Ethics Consultation Seminar for the Carolina Center for Genomic Studies (CCGS). November, 16, 2010 Dressler, LG and Friedman, I. Ethical Dilemmas in Genomic Research: An interactive seminar. A Research Ethics Consultation Seminar for the UNC Department of Genetics, November 9th, 2010. Dressler LG. The UNC Research Ethics Consultation Service: an update. Presented to the UNC Office of Human Research Ethics. October, 2010. Dressler, LG. Informed consent, specimen use and data sharing in today’s genomic research: Issues to Consider. Drug Induced Liver Injury Network (DILIN). NIDDK Conference, October 8, 2010. Dressler LG. Disclosure of individual results from genomic studies: Perspectives and Experiences of IRBs. NIH/NCI Symposium on Return of Research Results. Bethesda, MD. July 8-9, 2010. Dressler, LG. Addressing potential barriers to participation in pharmacogenomic studies. Cancer and Leukemia Group B. Pharmacology and Experimental Therapeutics Committee. June 25, 2010. Dressler LG. Adherence, comprehension and variability in drug vial directions in breast cancer patients taking oral chemotherapy. Cancer and Leukemia Group B. Pharmacology and Experimental Therapeutics Committee. June 25, 2010. Dressler, LG. Disclosure of individual research results from cancer genomic studies. University of Minnesota Meeting on Managing Incidental Findings and Research Results in Genomic Biobanks and Archives. January 26, 2010. Dressler, LG. Developing policy to address return of individual results in the ICGC. International Cancer Genome Consortium. ELSI subgroup meeting. Madrid, Spain. March 25, 2010. Dressler, LG. GWAS, dbGAP and the NIH data sharing policy: everything you always want to know but…University of North Carolina TrACS Education Seminar Series. April 20, 2010. Completed: (All presented by Lynn Dressler) . September, 2009: Integrating Pharmacogenomics into clinical practice: addressing the ethical, social, and policy issues. DPOP seminar. UNC Eshelman School of Pharmacy. July, 2009: Ownership and control issues in Biobanking. Research ethics seminar series for residents, fellows and graduate students. UNC Schools of Medicine and Public Health.

LYNN G. DRESSLER CURRICULUM VITAE

21

March 16, 2009: Genome-wide association studies and NIH GWAS data sharing policy: What IRBs need to know. IRB monthly meeting of staff and IRB chairs, UNC Office of Human Research Ethics. May, 2008 Participation in CALGB Pharmacogenonomic Studies: a preliminary analysis of PET Committee Protocols. Cancer and Leukemia Group B. Core Meetings. Pharmacology and Experimental Therapeutics Modality Committee. April, 2008. Integrating ELSI into the Scientific Process: the PERF approach. Presented at the 2nd International Congress on Ethical, Legal, Social Implications of Genetic Research. Cleveland, Ohio. November 17, 2008. Public Responsibility in Medicine and Research (PRIM&R) Conference. Invited panel discussant. "Ownership, Control and the Trusted Intermediary: Considerations for a Biobanking Model." Panel E23). Orlando, FL. November 18, 2008. Public Responsibility in Medicine and Research (PRIM&R) Conference. “Informed consent, future use of specimens, disclosure of results and other challenges in biobanking.(L Dressler) Co-discussant of workshop C4: Managing Specimen Repositories: Tools and Strategies.Orlando, FL. October, 2008. Improving clinical outcome through pharmacogenomics: ethical, social and policy issues. DPOP Graduate seminar. UNC Eshelman School of Pharmacy; September, 2008. Improving clinical outcome through pharmacogenomics: ethical and social considerations. GSK Futuristic Forum. Chapel Hill, NC. September, 2008. Toward Individualizing Therapy: Addressing Ethical, Legal, Social and Policy Issues (ELSP). Faculty seminar for Institute of Pharmacogenomics and Individualized Therapy. UNC Eshelman School of Pharmacy. July, 2008. Whose tissue is it anyway? Ethical issues in biobanking and use of human specimens in reserch. Research ethics seminar serues for clinicians. UNC School of Medicine. May, 2008 Consent for Pharmacogenomic Studies: a preliminary analysis of nine CALGB clinical trials. IPIT Faculty Seminar. UNC Eshelman School of Pharmacy. January 22, 2008. National Cancer Institute: Ca-BIG (Cancer bioinformation grid) data sharing workshop. “Sharing data and informed consent: ethical and policy issues to consider.” November, 2007 . Project 5. An ELSI Case Study Analysis of Large NIH Genetic Research Studies. Common Threads and Lessons Learned to Inform Policy Development. October 3, 2007: Ownership, Control and Human Specimen Research: Considerations for Biobanking and Oversight. NIH/NCI Custodianship and Ownership Issues in Biospecimen Research Symposium Workshop. Washington DC. September 5, 2007: “Biobanking and Disclosure of Research Results: Addressing the tension between professional boundaries and moral intuition.” UNESCO, Paris, France.

LYNN G. DRESSLER CURRICULUM VITAE

22

August, 8, 2007. AACR-FDA-NCI Cancer Biomarkers Collaborative. “Ethical, Legal and Policy Issues of Use of Human Specimens in Cancer Research.” Washington Dc. May 18, 2007: University of North Carolina, Institute for Pharmacogenomics and Individualized Therapy, Chapel Hill. 2nd Annual Drug Research Symposium. “ESLI as a facilitative science in pharmacogenomic studies.” Chapel Hill, NC February 24-28, 2007: 17th Annual National Interdisciplinary Breast Center Conference. “Ethical, Legal and Social Issues in Breast Cancer Genetic Research in the New Millenium of Genomic Medicine.” Las Vegas, NV. February 21, 2007: Centers of Excellence in ELSI Research (CEER) Annual Meeting. Washington DC. Disclosure of Genetic Research Results-An Overview of the NRSA F32 Training Grant. June 16, 2006: CALGB 50th Anniversary Meeting. CRA Genetic Research Workshop. Chicago, Il, “Ethical and Policy Issues in the Conduct of Genetic Research Studies in CALGB.” May 10, 2006: NCI/NHGRI The Cancer Genome Atlas(TCGA) Project. Datasharing Workshop. New York City, NY. “Ethical Issues, Data Sharing and the TCGA.” May 02, 2006: Massachusetts General Hospital. Breast Cancer Grand Rounds. “Ownership and Control of Human Specimens and Data: Policy Recommendations for Research”. February 23, 2006: Case Western Reserve University. Dept of Bioethics Works in Progress Series. “Disclosure of Genetic Research Results: Regulatory and Bioethical Perspectives”. December 08, 2005: Pathology Grand Rounds. Cleveland Clinic Foundation. Cleveland, Ohio. ”Access and Utilization of Stored Human Specimens: Challenges and Policy Issues.” November 10-11, 2005: “ Ethical Issues and Policy Recommendations for the Use of Human Specimens in Genetic Research: A 10 yr Retrospective Study”. Fondation Brocher:Value and Risks of Genetic Data Collections. Geneva, Switzerland. August 30-31, 2005: AFIP. Armed Forces Institute of Pathology Consensus Conference. “Ethical and Legal Issues of Ownership and Control of Human Specimens.” July 21-22, 2005: NIH/NCI/NHGRI.Cancer Genomics Workshop. Bethesda Md.

June 23-24, 2005: NIH/NCI Biospecimen Coordinating Committee Workshop on Biospecimen Access and Ethical, Legal and Policy Issues. Bethesda, MD. May 1-4, 2005: “Use of Stored Specimens in Research: Challenges and Solutions” International Society of Biological and Environmental Repositories Annual Meeting. Seattle, WA. November, 2004: Invited Participant. IBM Healthcare and Life Sciences. Worldwide Biobank Summit. Tarrytown, NY.

LYNN G. DRESSLER CURRICULUM VITAE

23

July, 2004: CALGB Solid Tumor Correlative Sciences Group Meeting. “HER2 and TOPO2 as predictors of response to dose-intense adriamycin.” CALGB 8541/150013. Philadelphia, PA. November, 2003: CALGB Plenary Session. “Human Specimens and Policy considerations in Correlative Science Research Studies.” June, 2000: CALGB Correlative Sciences Minisymposium on HER2. “Clinical Aspects and Technical Considerations of Measuring HER2 Status to Predict Response to Systemic Therapy.” November 21-23, 1999: HER2 State of the Art Conference. “Assessment of HER2 status by IHC, PCr, and FISH to Predict Outcome Following Adjuvant Doxorubicin Therapy: the CALGB Experience.” Montreux, Switzerland. October 7, 1999: National Cancer Institute/CTEP. Her2neu and antigen expression symposium. “Clinical correlates and technical considerations of IHC, FISH and PCR in breast cancer.” April 27, 1999: Cancer Genetics Network Symposium for Primary Care Physicians. “Ethical and Legal Implications of Genetic Testing.” September 14, 1998: National Cancer Instititue/ CTEP. Intergroup Tissue Banking Committee. “Quality Assurance Practices of Specimen Banking: the CALGB Model.” June, 1998: CALGB Correlative Sciences Solid Tumor Minisymposium: “P53: Biology, Technology and Correlative Sciences: An Overview.” June 24, 1998: Cancer and Leukemia Group B. “Limits and Benefits of Immunohistochemistry to Detect P53 Abnormalities in Breast Cancer.” January 9-10, 1998: American Joint Committee on Cancer ( AJCC). Prognostic Factors Consensus Conference. Breast Working Group. Invited member. Chair: David Page, MD. October 19-22, 1997: Breast Cancer Surveillance -National Consortium Meeting. “Biologic Differences in Screen Detected vs. Palpable Lesions: A Mammography Registry Working Group.” October 04, 1997: Body and Soul “97. A Symposium about Breast Cancer for Women and their Families. Genetic Testing and Legislative Efforts to Protect Privacy, Confidentiality and Prohibit Discrimination. March 12, 1997: North Carolina Medical Society. “Genetic Testing and NC Legislative Efforts to Prevent Discrimination.” February 27, 1997: North Carolina Oncology Society. “Genetic Discrimination: Legislative Efforts and Medical Issues.” November 5-6, 1996: NCI Developmental Diagnostics Working Group. Development of Clinical Resources. “The CALGB Clinical Trials Paraffin Block Repository.”

LYNN G. DRESSLER CURRICULUM VITAE

24

November 13, 1995: NCI/CTEP. Intergroup Breast Cancer Correlative Science Subcommittee. “Tissue Banking: Quality Control, Quality Assurance and Safeguards for Cooperative Group Studies.” Rockville, MD. April 18, 1995: NCI/CTEP. Intergroup Tumor Banks: A Working Group to Establish Guidelines. “Quality control/quality assurance issues for multiple assays.” November 16-17, 1994: NCI/CTEP. Clinical Correlative Science Studies in Solid Tumors. “Technical Issues in Immunohistochemistry.” Rockville, Md. June 23-26, 1994: College of American Pathologists Conference XXVI. “Clinical Relevance of Prognostic Markers in Solid Tumors.” Snowbird, Utah. October 5-10, 1993: NCI Chemoprevention Investigational Drug Unit. Workshop on Chemoprevention of Breast: Surrogate Endpoints and Agents in Short-term Clinical Trials. “DNA Flow cytometry as a surrogate endpoint: Clinical, Biological and quality control considerations.” Lake Tahoe, CA. August 26-28, 1993: American Cancer Society National Conference on Breast Cancer. Workshop: Prognostic Factors, Boston, MA. June 29-30, 1993: Canadian Society of Pathology International Conference. “Practical Aspects and Case Studies in DNA Flow Cytometry of Breast Cancer,” Banff, Canada. December 1-3, 1992: First International Cancer Molecular Biology Symposium. “The Clinical Utility of DNA Flow Cytometry Measurements in Breast Cancer: Predicting Patient Prognosis and Response to Chemotherapy,” Cairo, Egypt. November 24, 1992: American Society of Cytology. Cytoteleconference, Cytometric and Molecular Techniques in Diagnostic Pathology. Annenberg Center at Eisenhower, CA. September, 1992: Seventh Annual Meeting. Clinical Application of Cytometry. Meet the Professor Lunch Series. Conflicts and Controversies in DNA Flow Cytometry in Solid Tumors, Charleston, South Carolina. April 30-May 02, 1992: Twenty-fourth Annual Cancer Symposium: "Cytometry 2000. " DNA Flow Cytometry Application to Clinical Trials in Breast Cancer. Wayne State University School of Medicine, Detroit, Michigan. October 6-8, 1991: Rocky Mountain Cytometry Meeting, Plenary Session. Controls, Standards and Histogram Interpretation in DNA Flow Cytometry. Workshop Coordinator and Lecturer: DNA Flow Cytometry: Practical Issues, Clinical Relevance and Directions for the Future, Vail, Colorado. 1991-1992: Ortho Diagnostics Educational Symposium in Flow Cytometry. DNA Analysis in Solid Tumors. Workshop Series Lecturer Chicago, 1991. Los Angeles, 1992; New York, 1992. February 26-29, 1992: 4th International Conference on Adjuvant Therapy of Primary Breast Cancer. DNA Flow Cytometry: Its Clinical Impact in Primary Breast Cancer. Galen, Switzerland. International Consensus Conference.

LYNN G. DRESSLER CURRICULUM VITAE

25

September 18-20, 1991: UNM School of Medicine Workshop: Avoiding Pitfalls in Cancer Detection and Management in the Primary Care Setting. Fine Needle Aspiration in the Primary Care Setting, Albuquerque, NM. June 10-14, 1991: Annual National Flow Cytometry Course. Los Alamos National Laboratory and University of New Mexico School of Medicine. Instructor and Lecturer. June 17-19, 1990: American Society of Radiologists. Prognostic factors in Breast Cancer, Albuquerque, NM. September 12-15, 1990: Fifth Annual Meeting, Clinical Applications of Cytometry. Interpretation and Clinical Relevance of DNA Flow Cytometry Measurements, Charleston, South Carolina. June 18-21, 1990: NIH Consensus Development Conference. Treatment of Early Stage Breast Cancer. Prognostic Impact of DNA Flow Cytometry Measurements in the Node Negative Breast Cancer Patient. An Intergroup Study (INTO11), Bethesda, MD. March, 1990: NIH/NCI Workshop Meeting on Use of "In Vivo" BrdUrd to Study Cell Kinetics in Patients with Cancer and Other Diseases, Rockville, MD. September, 1989. The University of Western Ontario Symposium. DNA Flow Cytometry: Status and Controversies, London, Ontario, Canada. June, 1989: Cancer Symposium: St. Joseph Regional Hospital, Albuquerque,NM. June, 1989: ASMT National Meeting. Workshop in DNA Flow Cytometry, Washington, D.C. February, 1989: Becton Dickinson National User's Group Meeting, "Clinical applications of DNA flow cytometry." Workshop Session, San Francisco. November, 1988: Eastern Cooperative Oncology Group Meeting, General Session, Miami,Fl. July, 1988: UNM General Surgical Postgraduate Course, Albuquerque. June, 1988: National Coulter Flow Cytometry User's Meeting, New York City. April, 1988: Breast Cancer Symposium: Breast Screening and Identification of High Risk Patients, Memorial Hospital, Colorado Springs, Colorado; David Headley, Organizing Chairman. "DNA flow cytometric measurements and their relationship to clinical variables in node negative breast cancer patients. November, 1987: Regional Coulter Flow Cytometry User's Meeting, Chicago, Illinois. October, 1987: Southwest Oncology Group, Flow Cytometry Committee, Chicago. September 6-11, 1987: Third International Congress on Hormones and Cancer, Hamburg, Germany, K.D. Voigt, Organizing Chairman. 'The clinical application of DNA flow cytometry in breast cancer."

LYNN G. DRESSLER CURRICULUM VITAE

26

April, 1986: First International Congress on Cancer and Hormones, Rome, Italy, Stefano Iacobelli, Organizing Chairman. "DNA flow cytometry and steroid receptors." Unrefereed Work (Article/Monograph): Rakhra-Burris TK, Auman JT, Deverka P, Dressler LG, Evans JP, Goldberg RM, Havener TM, Hoskins JM, Jonas DE, Long KM, Motsinger-Reif AA, Irvin WJ, Richards KL, Roederer MW, Valgus JM, Riper M, Vernon JA, Zamboni WC, Wagner MJ, Walko CM, E Weck K, Wiltshire T, McLeod HL. Institutional Profile: UNC Institute for Pharmacogenomics and Individualized Therapy: interdisciplinary research for individual care. Pharmacogenomics. 2010 Jan;11(1):13-21. PMID: 20017668. Dressler LG and Bartow SA. DNA flow cytometry in solid tumors: practical aspects/clinical applications. Seminars in Diagnostic Pathology 6:55-82, 1998. Dissertation/Theses: Dressler, Lynn. The Need for Uniform Policy for the Use of Human Specimens in Genetic Research.. Doctoral Dissertation. UMI Dissertation Services (3100288). Proquest Information and Learning Center. Ann Arbor, MI. www.il.proquest.com. 2003. Dressler Lynn. The Development of a Radioimmunoassay for the Measurement of Plasma ACTH during the Acute Stage of Adrenal Regeneration. Masters Thesis in Pathology. State University of New York, Buffalo NY. 1981. TEACHING ACTIVITIES Courses taught/guest lectures: Spring, 2014. UNC Eshelman School of Pharmacy. DPOP Seminar. March 19, 2014. Graduate School. Spring, 2014. UNC Eshelman School of Pharmacy. PHCY432 Ethics and Law. Guest Lecture: Human Subjects Research: where we are, where we’ve been. March 21, 2014. Spring, 2014. Asheville School. Martin Luther King Convocation. The intersection of civil rights and human subjects research. January, 2014. Asheville, NC. Fall, 2013 UNC Gillings School of Public Health, Leadership Program in Health Policy. Personalized

Medicine and the Impact on Global Public Health. Ethics course. Fall, 2013 UNC Eshelman School of Pharmacy. Applied pharmacogenetics.Ethical, legal, social and

policy implications of pharmacogenomics research. Fall, 2012 Course Coordinator. PHCY801. Ethical Dilemmas in Research. Credit hours (1). Enrollment

(20), Contact hours teaching: 8 hours. Non-teaching contact hours: 131. Required for all first year ESOP graduate students from all divisions.

Fall, 2012 Guest lecturer. DPET 838. Applied Pharmacogenomics. Credit hours (2). Enrollment (22). Contact hours teaching: 2. Non-teaching contact hours: 16. Elective.

Fall, 2012 Guest Lecturer. SOPH. HPM. Public Health Genomics: Addressing ethical, legal, social and policy issues. Public Health Leadership Program in Health Policy. Enrollment (16).Contact teaching hours: 2; Non-teaching contact hours:8.

LYNN G. DRESSLER CURRICULUM VITAE

27

Fall,2012 Guest Lecturer. SOM Medical Student Module on Personalized Medicine. Ethical dilemmas in pharmacogenomics and the practice of medicine.

Spring,2012 Course Coordinator. PHCY432. Pharmacy Law and Ethics. Credit hours (3). Enrollment (147), Contact teaching hours: 8. Non teaching contact hours: 190. Jay Campbell (Law section). Required course of all third year pharmacy students in professional PharmD program

Fall, 2011 Course Coordinator. PHCY801. Ethical Dilemmas in Research. Credit hours (1). Enrollment (20), Contact hours teaching: 8 hours. Non-teaching contact hours: 131. Required for all first year ESOP graduate students from all divisions.

Fall, 2011 Guest lecturer. DPET 838. Applied Pharmacogenomics. Credit hours (2). Enrollment (24). Contact hours teaching: 2. Non-teaching contact hours: 16. Elective.

Fall, 2011 Guest Lecturer. SOPH. HPM. Public Health Genomics: Addressing ethical, legal, social and policy issues. Public Health Leadership Program in Health Policy. Enrollment (14).Contact teaching hours: 2; Non-teaching contact hours:8.

Fall, 2011 Guest Lecturer. SOM Medical Student Module on Personalized Medicine. Ethical dilemmas in pharmacogenomics and the practice of medicine.

Fall, 2011 Guest Lecturer. DPOP Seminar. Credit hours (1). Enrollment ( 12). Required. Contact teaching

hours: 1; Non teaching contact hours:9. Spring, 2011 Course Coordinator. PHCY432. Pharmacy Law and Ethics. Credit hours (3). Enrollment (147),

Contact teaching hours: 8. Non teaching contact hours: 190. Jay Campbell (Law section). Required course of all third year pharmacy students in professional PharmD program

Fall, 2010 Course Coordinator. PHCY801. Ethical Dilemmas in Research. Credit hours (1). Enrollment

(20), Contact hours (5 Lecture hours; present for each lecture). Required for all first year ESOP graduate students from all divisions.

July, 2010 CTSA Intensive Research Ethics Summer Training Course (CTSA and TraCs). Lecture hours (1). Access and use of human specimens in research: ownership, control and biobanking.

Fall, 2009 Course Coordinator. PHCY801. Ethical Dilemmas in Research. Credit hours (1). Enrollment (20), Contact hours (18 Lecture hours; present for each lecture). Required for all first year ESOP graduate students from all divisions.

Fall, 2009 Instructor. PHCY801. Ethical Dilemmas in Research. Credit hours (1). Enrollment (20),

Contact hours (4 Lecture hours). Fall, 2009 Instructor. DPET 832. Introduction to Applied Pharmacogenomics. Credit hours (2).

Enrollment (24), Contact hours (1 lecture hour). Elective PharmD and PhD. Fall, 2009 Instructor. DPOP899- Seminar. Credit hours (1). Enrollment (10). Contact hours ( 1 lecture

hour) Required all DPOP PhD students. Summer, 2009 Instructor. Intensive Research Ethics Course. Sponsored by UNC SOM TraCS, Dept of

Epidemiology and Dept of Surgery, Enrollment (~120), Contact hours ( 1 lecture hour). First year graduate students SOM, 4th year residents/fellows SOM. Required by some Departments and Divisions. Course Director: Dr. David Weber.

LYNN G. DRESSLER CURRICULUM VITAE

28

Spring, 2009 Instructor. PHCY432. Pharmacy Law and Ethics. Eshelman School of Pharmacy. University of North Carolina. Credit hours (3). Enrollment (146). Contact hours ( 1 lecture hour). Required PharmD.

Fall, 2008 Instructor. PHCY801. Ethical Dilemmas in Research. Credit hours (1). Enrollment (22),

Contact hours (1 Lecture hours). Required for all first year ESOP graduate students from all divisions.

Fall, 2008 Instructor. DPOP899 Seminar. Credit hours (1). Enrollment (10) Contact hours (1 lecture hour)

Required all DPOP PhD. Summer, 2008 Instructor. Intensive Research Ethics Course. Sponsored by UNC SOM TraCS, Dept of

Epidemiology and Dept of Surgery, Enrollment (~120), Contact hours ( 1 lecture hour). First year graduate students SOM, 4th year residents/fellows SOM. Required by some Departments and Divisions. Course Director: Dr. David Weber.

Supervision/mentoring of UNC students and trainees: (Fall 2007-present): 2014: PharmD 4th year student: May rotation. TBN 2014: PharmD 2nd Year student (UNCA): Annie Bernachi. Honors project in use of carbamazepine in Asians in neurology in Western North Carolina. 2013-2014:PY4 PharmD student: Danielle Schaeffer. Year long research project in pharmacogenomics.Frequency of pharmacogenomic variations (SNPs) in Western Carolina. With Mission Health, MAHEC and UNC-CH. 2013: PY4 PharmD student: Todd Knoepper. August, 2013. Month long rotation and extended research project related to implementation of pharmacogenomics in clinical pharmacy practice. With Mission Health, MAHEC and UNCH-CH. Ongoing or completed: Post doctoral fellow (2007-2009): Rene Sterling, PhD., UNC Center of Excellence in Ethical, Legal, Social Implications (ELSI) of Genetic Research (Center for Genomics and Society). ELSI and policy issues of early genomic variation studies (SNP and HAPMAP): what have we learned over the last decade to inform policy decisions? Completed 3/2010. Primary supervisor. Doctoral Student, Division of Pharmaceutical Outcomes and Policy (2009-2010). Stedman Stevens, MFS. UNC Eshelman School of Pharmacy. First year graduate student (2009). Pharmacogenomic Medical Education Meets the Business of Medicine (poster presented at 2009 National Consortium of Professional Health Care Educations in Genetics). Initial Mentor. PharmD. Honors Student (2010-present). Andrea Yuen PY2. UNC Eshelman School of Pharmacy. Patient Understanding of Pharmacogenomic Test Results in the LCCC Tamoxifen Trial in Breast Cancer. Primary mentor.

LYNN G. DRESSLER CURRICULUM VITAE

29

Oncology Pharmacy Residents (2010-present): Benyan Mohammed, PharmD and Maurice Alexander, PharmD. Cancer patient use of oral cancer agents with a food/fasting effect. Primary mentor. Doctoral Student, Division of Pharmaceutical Outcomes and Policy (2011-present): Aaron Katz. Utilization and cost effectiveness of chemotherapy for elder colorectal cancer patients. Doctoral Dissertation Committee Member. Doctoral Student, Division of Pharmaceutical Outcomes and Policy (2011-present). Melea Ward. Student Activity Committee (SAC). PRIOR TEACHING EXPERIENCE (1989-2007)

Spring 2007: Curriculum Development: New course in Research Ethics. Core course for new Research Ethics track for Masters Students in Bioethics. Case Western Reserve University. Cleveland Ohio. Spring 07: Course: International Women’s Health, Policy and Ethics. A comparison of health issues in the US compared to the Netherlands. CASE Department of Bioethics and CASE Mandel School of Applied Social Sciences. Fall 06: Public Health Leadership Program in Public Health Ethics. UNC School of Public Health. Department of Health Policy. Guest Lecturer. Public Health Ethics and Genomics. Spring 06: Critical Readings in Bioethics. Course Coordinator. Doctoral students. CASE Department of Bioethics, (Professor Patricia Marshall). Spring 06, April 18: Guest Lecturer. CWRU Master’s Program in Bioethics. Foundations of Bioethics. “Human Specimen Research and DNA Banking: Ethical Issues in Genomic Research”. Spring 06, April 4: Guest Lecturer. CWRU School of Law. Principles of Health, Law and Society. “Social, ethical and policy implications of genetic discrimination legislation”(Professor Sharona Hoffman). Spring 06, February 8: Guest Lecturer. Cleveland State University Law School. “Legal and ethical considerations of human specimen research and tissue banking”. (Professor Dena Davis). Spring 06, January 26: Guest Lecturer. CWRU Master’s Program in Bioethics. Foundations of Bioethics. “Genetic Discrimination: Ethical, Legal, Scientific and Policy Considerations.” (Professor Eric Juengst). Fall 05/Spring 06: Curriculum Development in Medical Genetics. In collaboration with mentor, Eric Juengst and Department of Medical Genetics (Georgia Weisner). Interactive Web-based learning modules for medical students. Bioethical considerations in Cancer Genetics. Fall 97, 98, 99 – present: CALGB Education Forum for Clinician-Researchers: Study Chair workshop for Solid Tumor Correlative Sciences Protocols: Policy , Process and Research Ethics. 1995-2006: UNC. School of Public Health. Spring: Epidemiology Guest Lecturer: Molecular Epidemiology Methods; Cancer Epidemiology: Immunohistochemical Methods, and Application in Epidemiology Studies.

LYNN G. DRESSLER CURRICULUM VITAE

30

Summer 04: UNC Workshop. Immunohistochemical and FISH Methods. Part I: Theory and Basic Principles. Part II: Pitfalls, Solutions and New Applications. Spring 04: Educational In-Service for Rex Pathology: Use of human specimens in clinical cancer research and technology development. Fall 03: Educational In-Service for UNCH Pre Care Nursing staff. Using human tissues in cancer research. Winter 02/03: Educational In-Service for Rex Healthcare Nursing Staff. A protocol to procure tissues for disease research. Fall 97/98: Public Health Leadership Program: Guest Lecturer: Health Policy and Politics Seminar: Genetic Testing and Prohibiting Discrimination: The North Carolina Legislative Experience. Fall 96/97: Cancer Prevention and Control Program: Guest Lecturer: Ethics and Genetic Testing (with Michael O’Malley); Genetic Testing, Genetic Information and Genetic Discrimination (with Jill Rosenblum, Esq). 1993-1994: University of North Carolina (UNC), Methods Course in Molecular Epidemiology. School of Public Health. Guest lecturer: Theory and Application of Immunohistochemistry Methods in Molecular Epidemiology Studies. 1991-1992: UNM School of Medicine. Center for Molecular and Cellular Diagnostics Fall and Spring Training Session. Didactic lecture program. Hormone Receptors, DNA Flow Cytometry Fluorescent In-situ Hybridization Techniques. Medical Student Lectures 1991-92: Pathology Block: Hormone Receptors, Flow Cytometry and Clinical Correlations in Breast Cancer. (Bill Black, M.D., Core Instructor). 1989-1991: UNM School of Medicine Fellow/Resident Training Program in Laboratory Methods. Center for Molecular and Cellular Diagnostics. Didactic lecture and hand-on training sessions. Biannual Training Program. Fall 1991: UNM School of Medicine. Primary Care Curriculum. 1st Year Medical Student Lecture: General Overview of Breast Cancer and Tumor Markers. (Bill Anderson, Ph.D., Core Instructor). Fall 1990: UNM School of Medicine. Pathology Block. 2nd Year Medical Students. Lecture: DNA Flow Cytometry, Clinical Applications and Breast Cancer. Fall 1989: UNC School of Medicine. Primary Care Curriculum. 2nd Year Medical Student lectures on cell kinetics, f low cytometry and prognosis. (Latif Kazim, Ph.D., Core Instructor). 1979-1980: Graduate Teaching Assistant, General Pathology Laboratory, SUNY, Buffalo COMMUNITY HEALTH EDUCATION PROGRAMS Completed: Asheville Rotary Club. Personalized Genomic Medicine: What’s in it for you? January 23, 2014

LYNN G. DRESSLER CURRICULUM VITAE

31

Asheville School. The Intersection of Science and Civil Rights: Remembering the past, preparing for the future. January 17th, 2014. Jewish Community Center. Personalized Genomic Medicine: Predicting response to drugs as well as disease susceptibility. Asheville, NC. July 18, 2013. Wellness Center at Walnut Cove. The Power to Change:Personalized Genomic Medicine. Asheville, NC .June 3, 2013. Biltmore Forest Country Club. Developing a Personalized Medicine Program in Western North Carolina. Asheville, NC. April 10, 2013. Ramble Wellness Center. What is Personalized Medicine and What can it mean for you and your family? Asheville, NC. April 24, 2013. Connecting for Cancer Committee. Personalized medicine and oncology: what’s in it for you? Asheville NC. April 30th, 2013. American Cancer Society Information Services. DNA Flow Cytometry and Cancer. Part of Cancer Information Service (CIS) program, September, 1990-1999. UNC Community Genetics Forum. September 15-16, 2006. Moderator and co-Speaker. Group, Genomics and Research Ethics. UNC/Duke Sponsored Symposium for Breast Cancer patients and families: Body and Soul. October 04, 1997; April, 1998. Genetics Session: Genetic Testing and Legislative Efforts to Protect Against Discrimination. Rose Kushner Breast Cancer Advisory Center. Reviewer for: If you've thought about breast cancer. 1993. Breast Cancer Digest Series, 1993. DNA Flow Cytometry and Prognosis in Early Stage Breast Cancer. New Mexico Tumor Registry Annual Workshop. Understanding and Interpreting Tumor Marker Assay Results in Breast Cancer, March, 1992, UNM School of Medicine. Valley High School Biology class lecture. What is cancer? Albuquerque, NM, February, 1992. UNM Sponsored Cancer Awareness in Albuquerque's Middle/High School Students. In collaboration with Dr. Black and Susan Chamberlin, UNM Program Development Office, 1987-1992. Instructor. UNM School of Medicine Workshop: Avoiding Pitfalls in Cancer Detection and Management in the Primary Care Setting. Fine Needle Aspiration, Albuquerque, NM, September 18-20, 1991. Innovations in Nursing Oncology Newsletter. Meniscus Health Care Communications, Philadelphia, PA. Article: What, Why, and How of DNA Flow Cytometry, May, 1989.

LYNN G. DRESSLER CURRICULUM VITAE

32

UNM Sponsored Workshop in Early Stage Breast Cancer. Panel Speaker and Discussant, September, 1989, Albuquerque, New Mexico. UNM Colloquium on Research on Women, 1988. Womens' Health Issues: Focus on Breast Disease/Breast Cancer/New Prognostic Tests. GRANTS, FELLOWSHIPS AND OTHER EXTRAMURAL FUNDING PENDING UNC TRACS Grant. Addressing ethnic disparity in participation on cancer pharmacogenomic studies in North Carolina. (PI-Fatimah Jackson; coI: Lynn Dressler). ACTIVE Subcontract: NIH NIDDK PO1 (PI: Paul Watkins) Drug Induced Liver Injury Network (DILIN)

Role: Genetic Ethicist 11/01/10- 12/31/12

1.2 cal

5-P50-HG004488 NIH/NHGRI (PI: Henderson, Gail) National Human Genome Research Institute/UNC Center for Genomics and Society

10/01/07 – 12/31/12

2.85 cal

Roles: Co-Investigator [Project PI : An ELSI Case Study Analysis of Large NIH Genetic Research Studies];Core Director: Research Ethics Consultation Service.

The UNC-CH Center for Genomics and Society focuses on newly emerging ethical, legal and social implications (ELSI) of genomics research as the field shifts its focus from small efforts to those on a much larger scale, raising a wide range of ELSI issues not apparent in smaller-scale efforts. The Center will conduct research projects on these ELSI issues; offer a research ethics consultation service for genomic researchers; facilitate policy initiatives informed by our research findings; and provide training, education, and community engagement particularly for underrepresented minorities to foster ELSI research on large-scale genomics. Completed: P50-HG003390 NIH/NHGRI Subcontract from Case Western Reserve University (PI: Eric Juengst)

10/01/08 – 07/31/09

1.2 cal

The InterCEER IRB/Research Study in Genetic Research Role: UNC Site PI The purpose of this study is to identify and document the perspectives and concerns of IRB members and staff in the review of genetic research studies. The overall goal of the study is to optimize interactions between genetic researchers and IRBs, protect individual participants and move quality science forward.

LYNN G. DRESSLER CURRICULUM VITAE

33

Special Description: 1-UL1-RR025747 Pisano E (PI) 07/01/08-06/13/2013 NIH UNC Clinical Translational Science Award; Ethics Core Role: Director, Research Ethics Consultation Service The development of this core has been put on hold. Furthermore, the salary support structure has changed from percent effort (10%) to the voucher system. As such, Dressler will NOT be continuing to serve as Director of this core at the present time. NHGRI/NRSA. (Dressler, PI). F32 NRSA Post doctoral Fellowship Award. Disclosure of individual results from genetic research studies: regulatory and bioethical perspectives. ($45,000). 9/06-9/07. NIH/NCI/NIA. (Dressler, PI). 1-U10-CA85790-01A1. “Tumor Markers to Predict Treatment Response in the Elderly Breast Cancer Patient: A Laboratory Companion to the CALGB Clinical Trial 49907”. Lynn Dressler-PI. ($1,116,842). 9/01/01-8/31/08. Extension approved 12 /19/2007. New ending date: 8/31/08. NIH/NCI/RO1. (Dressler, Site PI). Subcontract to UNC. “Evaluation of erbB2 and p53 to predict outcome following paclitaxel and doxorubicin: A Companion to CALGB 9344.” ($178,010/yr). 4/03-4/07. (RO1 PI: Daniel Hayes, University of Michigan). NIH/NCI/R01 (Dressler, Site PI) . Subcontract to UNC. “erB2 and p53 response and outcome after paclitaxel chemotherapy. “ ($104,970). (9/14/99-03). (R01 PI:Lyndsay Harris. DFCI). NIA/NIH/U10 (Dressler, co-PI). “ Laboratory Studies in Elderly Women with Breast Cancer.’ William Cance, PI. ($915,305). (7/1/99-6/30/03). NIH/NCI: (R01) (Dressler, co-Investigator). “Fatty acids and tumor characteristics in breast cancer.” PI: Lenore Kohlmeier. Subcontract to UNC IHC Lab.. 9/1/97-8/31/01. CALGB Breast Cancer Research Foundation (BCRF): HER2 FISH and prediction of response in CALGB 9344. Lynn Dressler-UNC PI ($50,000). CALGB Breast Cancer Research Foundation (BCRF) Award (Dressler, PI): “Correlative Studies of erbB2/HER2, p53 and other molecular markers to predict outcome to HERCEPTIN and Paclitaxel. A Companion to CALGB 9840.” ($35,000). 2/01/04-1/31/05. NIH/NCI. Ca-BIG Grant (Dressler, coPI). “Participation in the NCI ca-BIG Tissue Banking and Pathology Workspace.” PI: Leigh Thorne. 2004, 2005. CALGB Breast Cancer Research Foundation (BCRF) Award (Dressler, PI): “Correlative Studies of erbB2/HER2 and p53. Companion to CALGB Protocol 9344/INT Protocol 0148”. ($30,000). 4/1/02-3/31/05. CALGB Chairman’s Development Award (Dressler, PI): “Correlative Studies of TOPOII by FISH in CALGB 8541. ($25,000). 4/1/02-3/31/05. CALGB/Vysis contract (Dressler, PI). “Her2-neu prediction of response to therapy using fluorescent in situ hybridization: CALGB 8869.” ($50,000). 1998-99.

LYNN G. DRESSLER CURRICULUM VITAE

34

USAMR: DAMD17-94-J-4114 (Dressler, coPI). Subcontract to UNC. “Linkage of molecular and epidemiologic breast cancer investigations with treatment data.” PI: Robert Millikan. ($225,668). 9/1/96-9/30/99. NIH/NCI: U01CA70040-01 (Dressler, co Investigator, Project PI). “Cancer surveillance research in North Carolina, “PI. Bonnie YankaskasProject 2: “Biological differences in interval vs. screen-detected breast cancers”. Project 2 Award: ($381,696). 10-1-95 to 8-01-99 NIH/NCI: U01CA64061 (Dressler, PI). Subcontract to UNC. “Her-2 oncogene and response to dose intensive therapy.” Original PI: Edison Liu. PI Transfer (1998) to Lynn Dressler. ($311,206). 9/1/96-3/31/99. NIH/NCI/CALGB U10 (Dressler, PI): Subcontract CALGB 8961. “Ras mutations in myelodysplasia.” PI: Lynn Dressler. Original PI: Edison Liu. PI Transfer (1998) to Lynn Dressler .($320,294) 9/1/96-3/31/98. UNC-LCCC Seed Grant (Dressler, PI). “Angiogenesis as a surrogate marker for lymph node involvement in “good prognosis” invasive breast cancer.” PI: Lynn Dressler. ($10,000). 4/1/96-3/31/97. NIH/NCI/Eastern Cooperative Oncology Group (ECOG) Special Project Subcontract Award (NIH) (Dressler, PI). "Evaluation of DNA flow cytometry measurements of ploidy and S phase in stage II breast cancer patients." ($52,196) April, 1989 - November, 1993. NIH/NCI Training Predoctoral Fellowship Award (Dressler, PI). University of Arizona Health Science Center. Comprehensive Cancer Center. Tucson, AZ. 1992-1993. University of New Mexico Cancer Center Cigarette Tax Fund Research Award (Dressler, PI): "Development of a multiparameter flow cytometry system to evaluate heterogeneous breast cancer cell populations" ($13,545). 7-1-88 to 6-30-92. NIH/NCI/Eastern Cooperative Oncology Group: Addendum to Special Project Award (Dressler, PI): "The clinical significance and therapeutic impact of immunohistochemical evaluation of the Her2-neu oncogene product and steroid hormone receptors in stage II breast cancer." ($25,891) 10-1-89 to 9-30-90. Susan G. Komen Breast Cancer Research Scholar Award (Dressler, PI): "Identification of high risk stage I breast cancer patients." ($49,988) 12-1-86 to 11-30-87. NIH/NCI Biomedical Research Support Grant /Cancer Therapy and Research Center of San Antonio (Dressler, PI): "Prediction of recurrence and therapy response in node negative breast cancer patients by DNA flow cytometry." ($18, 263), 4-1-86 to 3-30-87. PROFESSIONAL SERVICE To Discipline: 2009-present NIH/NHGRI Study Section. Special Emphasis Panel. Review of P50 and P20 Centers of

Excellence in Ethical, Legal and Social Implications of Genetic Research. eMERGE Centers. 2009-present NIH/NCI caHUB (Cancer Human Specimen Biobank). Invited Member. Ethical, Legal, Social

Implications Working Group. (Chair: Joan Scott) 2008-present Affiliate Member. Pharmacogenetics Research Network (PGRN). 2008-present NCI/NHGRI Cancer Genome Atlas External Scientific Steering Committee. 2008-present NCI/NHGRI International Cancer Genome Consortium (ICGC). Invited

LYNN G. DRESSLER CURRICULUM VITAE

35

member. Policy and Ethics Working Group. (Chair: Bartha Knoppers) 2008-present Electronic Medical Records and Genetic Research (eMERGE) Consortium. Member, Disclosure of results, IRB issues and Data Sharing working groups (Chair: Ellen Clayton Wright). 2007- 2009 Center for Disease Control and Prevention (CDC), Evaluation of Genomic

Assays for Prevention and Practice (EGAPP). Nominated member. Stakeholders Committee.

2007-present Cadre Member. Pharmacology and Experimental Therapeutics and Breast Committees. Cancer and Leukemia Group B. 2002-present Cadre Member. Ethics Subcommittee of CARE (Communication, Research, Ethics and

Underserved Minorities Committee).Cancer and Leukemia Group B (CALGB.) 2006- present Reviewer: Pharmacogenetics Journal, PLOS. Clinical Pharmacology and Therapeutics,

Community Genetics (now Public Health Genomics), Genetics in Medicine 1996- present Reviewer: CANCER, J National Cancer Institute (JNCI), J Clinical Oncology (JCO), J Clinical

Cancer Research, Breast Cancer Research and Treatment (BCRT), Cancer Prevention, Detection and Epidemiology.

Completed service: 2004-2008 Chair, Regulatory and Ethics Subcommittee. NCI Clinical Trials Group Banking Committee 2007-2009 AACR-NCI-FDA Cancer Biomarkers Collaborative. Biospecimen/Clinical Assay Group 2007 Board Member, Education Network to Advance Cancer Clinical Trials (ENNACT) 2006-2007 Co-Chair, Biospecimen and correlative science advisory committee (BACSAC). CALGB. 2006 NIH/NCI Reviewer for TCGA contracts. 2006-2009 NHGRI ELSI: Working Group for reconsent issues in genomic research. 2006-2009 NHGRI ELSI: Medical Sequencing Informed Consent and Disclosure Subcommittees. 2006-2009 NCI, Advisor Office of Biorepositories and Biospecimen Research (OBBR). First Generation Guidelines for Human Specimen Research. Ethics Section. 2005-2007 Coordinator, Research Ethics Consultation Service, Center for Genetic Research Ethics and Law (CGREAL), Case Western Reserve University, Dept of Bioethics. 2005-2007 Coordinator, Best Practices for Genetic Research Studies: A city wide User’s Group, Cleveland, Ohio. 2001-2006 NCI Pathology Common Data Elements Committee. Breast Cancer Subcommittee. 2005-2006 Chair. Solid Tumor Correlative Sciences Steering Committee. CALGB.. 2001-2005 Co-chair. Breast Correlative Sciences Working Group. CALGB. 1996-2005 Vice Chair. Solid Tumor Correlative Sciences Committee. CALGB, 2004-2005 Invited member, North Carolina Genomics Task Force. Policy and Ethics SubCommittee. 1998-2004 Chair, Quality Assurance Subcommittee. NCI Clinical Trials Intergroup Banking Committee. 1996-2004 Vice Chair. Solid Tumor Correlative Science Committee. Cancer and Leukemia Group B (CALGB). 1997-2004 Academic Consultant. North Carolina Medical Society. Cancer Committee. 1994-2004 Cadre Member. CALGB Steering Committee/Policy Development: Ethical Considerations of

Germline DNA studies in Breast Cancer Clinical Trials. 1993- 2004 Scientific and Tissue Bank Coordinator. CALGB. Solid Tumor Correlative Sciences Committee. 1996-2001 NC Public Policy Committee of the North Carolina Advisory Committee on Cancer Control and

Coordination. Cadre Member 1996-1999 Member, North Carolina Advisory Committee for Cancer Control and Coordination: Ad-Hoc

Committee for Genetic Discrimination Legislation. (Chair: Dr. Ronald Levine, NC Medical Director).

1993-1998 Editorial Board. Communications in Clinical Cytometry.

LYNN G. DRESSLER CURRICULUM VITAE

36

1990-1998 Scientific Board. CYTOMETRIE CLINIQUE, Editor, Jean Louis Moll. 1996-1997 Staff Coordinator. North Carolina Cancer Control and Coordination Advisory Committee-Early Detection Subcommittee. (Chair: Dr. Barbara Rimer) 1994-1997 Associate Editor. Current Protocols in Flow Cytometry. Wiley-Liss, NY. 1992-1994 Associate Editor. International Society of Analytical Cytology(ISAC) Handbook of Flow

Cytometry Methods. 1988-1993 Executive Member of Eastern Cooperative Oncology Group (ECOG). Breast Biology

Subcommittee, Member Pathology Committee. 1986-1993 Executive Member of Flow Cytometry Committee, Southwest Oncology Group. Within UNC-Chapel Hill: 2010-2013 UNC Eshelman School of Pharmacy Curriculum Committee 2009-2013 UNC Eshelman School of Pharmacy Conflicts of Interest Committee 2008-2010 UNC Biomedical Institutional Review Board, Member Committee A 2007-2011 UNC Center for Genomics and Society, Director Research Ethics

Consultation Service (RECS) 2007-present UNC TraCs Biobanking Committee. 2005-2008 UNC Vice Chancellor’s ad hoc Committee on Tissue Banks and DNA Repositories. 2004-2007 Special Consultant. UNC CEER Planning Grant. Biobanking, DNA Repositories and Large Scale Genetic Studies issues. (PI Dr. Donald Bailey, Gail Henderson). 2004-2007 Ad hoc consultant, UNC LCCC Research Ethics, Honest Broker System, Biobanking. 2004-2006 Chair. UNC LCCC Oversight Committee for Genetic Research. 1993-2006 Director, UNC Breast SPORE Tissue Procurement and Analysis Core Facility. 1996-2005 Director, UNC LCCC CORE Tissue Procurement and Analysis Facility. 2000-2003 Coordinator. UNC LCCC Oversight Committee for Genetic Research 1995-2003 Member, Ethics Committee of the Carolina Breast Cancer Study. Specialized Program for

Research Excellence (SPORE) 1994-2000 Member, Steering Committee: CALGB 9484: Linkage of Molecular and Epidemiological

Breast Cancer Investigations with Treatment Data: A Specialized Registry.